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ABSTRACT
Lipids have been utilized to increase the bioavailability of poorly soluble drugs which
resulted in with advent of High Throughput Screening (HTS). Although lipids have
been used to improve bioavailability of a few drugs for almost twenty years, they are
still not well characterized. There are limited publications about the effects of
physicochemical properties of the lipid vehicle, such as class of lipid (i.e. glyceride,
propylene glycol ester), fatty acid chain length, MW and polarity on lipid solubility,
formulation and bioavailability of poorly soluble drugs. Knowledge of such
relationship can improve quick screening of these vehicles. The goals of this study are
to identify physicochemical properties of the lipids, to investigate the relationship of
these properties with solubility of the model drugs, namely nifedipine and
griseofulvin, to design lipid-drug formulations with Cremophor EL, to evaluate in
vitro dissolution of selected formulations and to compare the bioavailability of
nifedipine from the formulations tested. It has been shown that the lipids used
improved the solubility of nifedipine and griseofulvin compared to the solubility of
drugs in water. Calculated solubility parameter was not sufficient to predict the
solubility of the drugs in the lipids. Calculated and measured properties of lipids
analyzed with stepwise regression analyses showed that MW, dielectric constant,
surface tension and fatty acid chain length are the common factors that govern the
lipid solubility. However. the estimates of each factor were different for each drug
indicating that the nature of the drug played an important role in lipid solubility.
Incorporation of Cremophor EL. a nonionic surfactant into lipid-based nifedipine
formulation enhanced the solubility and dissolution of nifedipine. The solubility of
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nifedipine showed a linear correlation with increasing surfactant concentration. While
solution rate was dependent on the type of lipid used, the nature of the lipid had no
affect on the dissolution of nifedipine in presence of the surfactant. Dissolution of
nifedipine from the lipids showed that as the fatty acid chain length increases, the
dissolution rate increases. This is due to lower solubility of nifedipine in the lipids that
have longer chain length. The effect of lipids on dissolution rate and extent of
nifedipine showed that even though physicochemical properties of lipids (HLB,
interfacial tension, viscosity, density) and solubility of nifedipine in lipids play a role,
only partitioning of the drug from lipid to the dissolution medium and the particle size
of the formulation in dissolution medium provided a good correlation with dissolution
extent of nifedipine. The bioavailability of nifedipine obtained with different lipid
formulations in beagle dogs showed that the type lipid and surfactant used in the
formulation play important roles. Dissolution is a good predictor for in vivo
performance of nifedipine lipid formulation when it was formulated with nondigestible lipids (mostly mono-glycerides). Although, the solubility of nifedipine in
lipids, the particle size of the formulation in dissolution medium and partitioning of
the drug from the formulation to dissolution medium seem to affect the in vivo
performance of the drug, dissolution performance of the formulation and digestibility
of the lipid used in the formulation are the major factors in bioavailability of
nifedipine from the lipid-based formulations.
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This work has been prepared in accordance with the manuscript fom1at option for
dissertation preparation, as outlined in Section 11 of the Graduate Student Manual of
the University of Rhode Island. Contained within is the body of the work divided into
three sections.

Section I includes one manuscript which introduces the subjects of dissertation to the
reader and specific objectives of my research.

Section II includes three manuscripts, containing the findings of the research. These
manuscripts are written in the format required by the journals to which they will be
submitted.

Section III contains appendices and bibliography, arranged in alphabetic order by the
author's last name.
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Abstract: The advent of High Throughput Screening (HTS) and Combinatorial
Chemistry in drug discovery has resulted in compounds which are more lipophilic,
having log P > 4. As a consequence, the application of lipid delivery systems has more
recently received greater attention in the pharmaceutical industry. This paper presents
a review of lipid vehicles used in the oral drug delivery of poorly soluble drugs. Lipids
that are available in the US market are defined and classified and different types of
lipid formulations have been cited from the literature. Formulation considerations and
the effect of lipids on lipolysis as well as systemic and lymphatic drug absorption are
discussed. In addition, the characterization techniques of formulation, stability, in vivo

I in vitro correlation and absorption mechanisms for lipid-based formulations are
summarized.

(
Keywords: Lipid vehicles, lipid-based formulations, formulation considerations,
lipolysis, lymphatic absorption, characterization techniques

Glossary:
DG: Diglyceride
DSC: Differential scanning calorimeter
GER: Gastric emptying rate
GML: Glyceryl mono-laurate
GMO: Glyceryl mono-oleate
GMS: Glyceryl mono-stearate
HLB: Hydrophile-lipophile balance
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IT: Interfacial Tension
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L: Liquid
LCT: Long chain triglyceride
LFDS: Low frequency dielectric spectroscopy
MBLA: N-a-methylbenzyllinoleamide
MCM: Medium chain monoglyceride
MCT; medium chain triglyceride
MG: Monoglyceride
MP: Melting point
NIA: Not available

PEG: Polyethylene glycol
PGG: Polyglycolized glycerides
S:Solid
SEDDS: Self-emulsifying drug delivery system
SMEDS: Self-microemulsifying drug delivery system
SEOF: Self-emulsifying oil formulation
SLN: Solid lipid nanoparticles
SS: Semisolid
TG: Triglyceride
TBUs: Tributyrin units
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1. INTRODUCTION

During the development of oral pharmaceutical dosage forms of new drug candidates,
the formulation scientists are faced with many challenges. One challenge which is
very often encountered is poor bioavailability. With the advent of High Throughput
Screening (HTS) and Combinatorial Chemistry in drug discovery, modern drug
molecules are more lipophilic which often results in their being poorly bioavailable.
The use of lipid vehicles has generated considerable attention in recent years for
improving the bioavailability of poorly soluble drugs as one of the approaches to
improve their oral bioavailability. The well-known effect of food in improving the
bioavailability of many poorly soluble drugs such as griseofulvin, carbamazepine and
danazol is evidence that lipids can be beneficial to drug absorption (Charman et al.,
1992, 1993, 1997; Humberstone and Charman, 1997). Lipids can improve the
bioavailability of drugs through several mechanisms such as by enhancing solubility/
dissolution (Pozzi et al. , 1991; Sheen et al. , 1991; Charman et al. , 1992; Shah et al.,
1994; Matuszewska et al., 1996; August et al., 1997), by providing uniform gastric
emptying and uniform absorption rate (Yamahira et al, 1979a, b, 1980) and by
increasing lymphatic absorption (Cheema et al., 1987; Charman and Stella, 1992;
August et al., 1993; Porter and Charman, 1997).

Although lipids have been used to improve bioavailability for almost twenty years,
they are still not well characterized. In addition, mechanistic studies that explain the
effect of physicochemical properties of lipid vehicles on formulation and drug
absorption, the use of appropriate techniques to characterize lipid-based systems and
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in vivo/in vitro correlations have not been adequately addressed and well understood.
In this paper, information regarding these issues is collected and discussed in the
following order: (I) definition and classification of lipids, (II) type of lipid
formulations, (III) formulation considerations of lipid based systems, (IV) effects of
lipids during the absorption of poorly soluble drugs and (V) characterization
techniques of lipid based systems.

2. DEFINITION AND CLASSIFICATION OF LIPIDS
Lundberg and Weiner define lipids as a "chemically heterogeneous group of
substances, having in common the property of insolubility in water but solubility in
non-polar solvents" and the science that deals with lipids is referred to as 'Lipidology'
(Lundberg, 1984; Weiner, 1993). However, many lipids have some limited water
solubility and are commonly used as vehicles in pharmaceutical formulations. Lipids
can be classified based on chemical characteristics such as carbon chain length of fatty
acid and ester type rather than on their solubility. Surfactants also fall into this
category. Sometimes, there is no distinct difference between a lipid and a surfactant.
Some lipids have surface active properties, for example medium chain monoglycerides
can lower interfacial tension and easily dispersed in aqueous media.
Types of lipids include natural and synthetic fatty acids, oils, fats, waxes,
phospholipids and some surfactants. Fatty acids can be defined as organic acids with
straight hydrocarbon chain and can be classified based on the length of the
hydrocarbon chain. Fatty acids with hydrocarbon length C2-C6 are considered to be
short~hain,

with Cs-C12 medium-chain and with C 14 and higher long-chain fatty acids.
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Oils are unsaturated fatty acid esters of glycerol whereas fats are saturated fatty acid
esters of glycerol. Waxes are the esters of fatty acids with alcohols other than glycerol.
Surfactants that are in the lipid category are commonly fatty acid esters of PEGs.
Lipids also include some lipid fractions and synthetic accommodations of glycerides
with PEG esters. The fractionated esters are seldom pure and tend to exist as mixtures
of various combinations. Commonly used lipid vehicles in oral drug delivery have at
least one fatty acid esterified with a polyol such as glycerol/s, propylene glycol or
PEG. Tables 1 A-F present lipid vehicles commonly used in the US pharmaceutical
industry in oral drug delivery products. Phospholipids are excluded from the scope of
this paper since they are mainly used in parenteral formulations.

3. TYPE OF LIPID FORMULATIONS
In addition to simple solutions of drug molecules in lipids, solid dispersions, micelles,
liquid crystals, emulsions including self-emulsifying systems and microemulsions and
solid lipid nanoparticles (SLN) are also commonly used formulation approaches for
lipid based systems.

Because of their unacceptable taste, many lipid formulations are administered in soft
or hard gelatin capsules as unit dosage forms.

Lipid formulations were classified by Pouton (1999 and 2000) as Types I, II, IIIA and
IIIB. This classification is based on composition such as amount(%) of the glyceride,
surfactants and hydrophilic co-solvents and physical attributes including particle size
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of the dispersion, impact of aqueous dilution and digestibility (Table 2). This
classification can be useful in comparing different studies and can serve as a guide to
estimate physicochemical properties of the lipid formulation of interest. The
incorporation of a drug in the vehicle can significantly change the physicochemical
properties of the system in terms of particle size and dispersibility following aqueous
dilution and may result in a shift of the system from one type to another. Therefore,
such classification cannot be a significant predictor of the physicochemical properties
of the end product and is especially so for surface active and high dose drugs. The
classification of lipid systems as solutions, suspensions, solid dispersions, micelles,
emulsions including self-emulsifying systems (SEDDS) and microemulsions and solid
lipid nanoparticles appears to be universally acceptable. Examples of these
formulations that are cited in the literature are summarized in Tables 3- 9. As can be
seen from these tables, SEDDS are the most commonly used formulations and drugs
with molecular weights around 300 are the most commonly used model drugs. By
presenting these tables, we wanted give a guideline for the readers. Additional
information on selected examples of lipid solutions, suspensions, emulsions and solid
dispersions can be found in a review by Humberstone and Charman (1997), SEDDS
by Pouton (1997) and Gershanik and Benita (2000), and solid lipid nanoparticles by
Muller et al. (2000).

Despite the numerous studies shown in these tables, only a relatively few commercial
formulations of lipid based systems are available on the market. These are
cyclosporine (Sandimmune™ and NeoraFM, Novartis), saquinavir (Fortovase™,
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Roche), ritonovir (Norvir™, Abbott) and fat-soluble vitamins. Possible reasons for the
rarity of commercially available lipid-based products are the physical complexity of
lipids, reliability of supply (quality), lack of knowledge of mechanisms of drug
absorption and fate of the lipid in the gastrointestinal tract. An additional factor may
be the limited solubility of pharmaceutical compounds in lipid solvents. Overall, the
lack of mechanistic understanding of the role oflipids in drug absorption is a key
reason for their underutilization for formulation development.

4. FORMULATION CONSIDERATIONS OF LIPID BASED SYSTEMS
4.1. Selection of lipid vehicles

For a lipid to be used in a drug delivery system it must be safe and ,therefore, the first
requirement for these excipients is to be classified as GRAS (generally recognized as
safe) materials. The majority of lipids used in marketed products do fulfill this
requirement. In lipid formulation development, potential toxicity of any surfactants
need should be considered carefully. This evaluation includes not only the type of the
surfactant but also the concentration/dose (Swenson et al., 1994).

Drug solubility in the lipid is an important factor in the selection of the lipid as a
vehicle. Determination of solubility of drugs in lipids is a major challenge since
solubility of drugs in lipid based system is a poorly understood concept. There is no
published systematic study to show a relationship between solubility in lipid and
physicochemical properties of the drug such as molecular weight, logP and melting
point. It has been shown that in the case of an investigational anti-HIV agent solubility
\,
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increases as ester bond concentration of lipid increases (Anderson and Marra, 1999).
Determining the solubility parameter of a lipid vehicle and thereby quantifying its
cohesive energy can offer a solution for screening of lipid candidates. Calculated
solubility parameters can be used for this purpose. The closer the solubility parameter
of a drug to that of a lipid vehicle, the more soluble would be that drug in such a
vehicle (Dumanli et al., 2000).

The formulation scientist should also take into account the fact that the solubility of a
drug may change due to the changes in the vehicle during the products shelf life. For
example, partitioning of water from the gelatin capsule shell into the lipid can have a
significant effect on the solubility of the drug. Therefore, the hygroscopicity of the
lipid used in such formulation should be carefully evaluated (Fig. I). Furthermore, the
dissolved drug in a solid lipid may precipitate out during processing when the
formulation is cooled down to room temperature. The solubility of a drug in solid
lipids should be significantly higher than final concentration in the formulation.
Solubility should be determined under extreme conditions that the product would be
subjected to during processing, manufacture and its shelf life. It should also be kept in
mind that the release of a drug from the vehicle is the inverse function of its solubility
in the lipid solvent. Therefore, chemical potential (concentration/solubility) and
partitioning of the drug from lipid to immediate aqueous environment should be
considered in addition to drug solubility and concentration (Armstrong and James,
1980).
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To optimize both the lipid solubility and release of the drug, co-solvent and
surfactant/s may be added to the formulation. Cremophor EL a commonly used
surfactant has increased the solubility oflipophilic drugs, griseofulvin and nifedipine,
Table 10. The ratio of co-solvents should be optimized to avoid potential precipitation
of the drug following aqueous dilution. Lipid vehicle, surfactant, co-solvent and drug
combinations can be evaluated upon aqueous dilution using phase diagrams (Shah et
al., 1994; Constantinides, 1995 and Kim et al. 2000).

4. 2. Effect of HLB
As mentioned above, there is no distinct difference between a surfactant and a lipid
that is surface active. In order to achieve good dispersibility and absorption, it may be
necessary to use both surfactant/sand lipid vehicle/sin formulations such as SEDDS,
emulsions and microemulsions. HLB plays an important role in the selection of lipid
vehicles in these types of lipid formulations. Even though most of the lipids have no
surface active properties, some of them like medium chain mono-glycerides and PEG
esters exhibit surfactant properties. These can have HLB values up to 14, (Table lF).
HLB of a lipid vehicle/surfactant can affect the solubility of a drug. For example, as
the HLB increases, the solubility of griseofulvin increases (Fig. 2) (Dumanli et al.,
2000). The effect of HLB on drug release rate from a lipid based formulation is shown
in Fig.3. HLB value of a lipid vehicle also significantly influences the selfemulsification and dissolution properties of a SEDDS formulation (Shah et al., 1994,
Kim et al., 2000 and Nazzal et al., 2002).
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4. 3. Drug Loading

The factors determining the loading capacity of a drug in solid lipid nanoparticles
include as (I) drug solubility in molten lipid, (II) miscibility of molten drug in a lipid
melt, (III) chemical and physical structure of solid lipid matrix and (IV) polymorphic
state of lipid material (Muller et al. 2000).

It is not advisable to use a saturated solution in solid lipids because some of the drug
may precipitate out at ambient temperature causing structural variations within the
system. Resulting crystalliz.ation may lower the bioavailability.

In lipid formulations with high drug concentration, determination of the saturation
point of the drug becomes a critical factor in the formulation design. If the drug
precipitates out in gastrointestinal tract, its bioavailability may be reduced. However,
the use of appropriate lipid vehicle at the optimum level can overcome this problem as
it has been shown in the case of lipid formulation ofDMP 323 , a poorly soluble HIV
protease inhibitor. A formulation containing Gelucire 44/14 (a mixture of glycerides
and PEG esters) increased DMP 323 aqueous solubility and dissolution rate, and
enhanced the bioavailability at high doses (August et al. , 1997).

Drug loading can also affect physiochemical properties of the formulation. For
example, increasing concentration of L-365 ,260, a poorly soluble benzodiazepine
derivative, caused changes in droplet size of emulsions prepared with Labrafil M
2125CS (Craig et al. , 1993).

11
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A poorly soluble drug substance dissolved in MCM can significantly affect
rheological properties and particle size of the formulation as a function of its
concentration (Fig. 4). Change in slope of zero shear viscosity vs. concentration shows
that the lipid solvent cannot accommodate too many solute molecules so that the drug
reaches the saturation point where further addition of the drug may cause
entanglement of the molecule (Dumanli and Kislalioglu, 1999).

Concentration and surface active properties of a drug in a lipid vehicle can modify the
phase transition of a lipid. However, such an effect is dependent on the properties of
the drug. For example, griseofulvin facilitates liquid crystal formation in glyceryl
mono-oleate (GMO) at saturated concentration whereas nifedipine does not have the
same influence. At the physiological temperature, GMO forms a cubic phase via
reverse micellar transformation which is concentration specific. Above a certain
concentration, lipophilic drugs such as ibuprofen and propranolol transformed the
cubic phase into an inverted hexagonal phase where the system becomes less viscous
resulting in modification of the release properties (Chang and Bodmeier, 1997). As the
water content of cubic phase is increased, the system may become more viscous
(Engstrom, 1990) and may sustain the release of the drug. On the other hand this
phenomenon may enhance the stability. Enhanced stability of cefazolin and
cefuroxime in glyceryl mono-oleate cubic phase gels showed its potential as a
chemical stability enhancer, protecting the antibiotics from P-hydrolysis and oxidation
as a result ofreduced motility of water, in the gel (Sadhale and Shah, 1998).
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4. 4. Manufacturing and Stability Considerations

Most of the lipid-based formulations especially the ones that contain semi-solid/solid
lipids involve the application of heat during their preparation. Duration of heat
application, temperature and cooling rate can have a significant effect on the quality
and stability of the final product. Scale-up processes of these formulations are also
challenging because duration of heat application and cooling rate can change with
increased scale. Therefore, optimal process should be always considered during
development to assure scale-up certainty and robustness. DSC and viscosity
measurements can be useful tools to monitor the effect of temperature, holding time
and cooling rate. Many lipids may exhibit polymorphic transitions upon storage or
during processing. It has been shown that cooling rate can affect endotherms of
Gelucires upon aging (Sutananta et al., 1994).

(

Most of liquid and semi-solid lipids contain unsaturated bond that photo- and autooxidize. Peroxide formation with oxidation can damage the drug and induce toxicity.
Lipid peroxides may also form due to autoxidation, which increases with unsaturation
level. Hydrolysis of the lipid may be accelerated due to the pH of the solution or from
processing energy such as ultrasonic radiation (Weiner, 2002). Including an antioxidant (i.e. cx:-tocopherol, propyl gallate, ascorbate or BHT) can be necessary in lipidbased formulation. Hygroscopicity of the vehicles (Fig. 1) is also important for
stability of gelatin capsules. Water migration into capsule fill can cause cracking of
the capsule shell.

(
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5. EFFECTS OF LIPIDS DURING ABSORPTION OF POORLY SOLUBLE
DRUGS
5.1 Lipolysis and systemic absorption
Understanding of lipid digestion process is important in design of lipid-based
formulations. Digestion process involves 3 basic steps (Fig. 5): (I) dispersion of lipid
into gastric media and emulsification by gastric motility, (II) enzymatic hydrolysis of
tri-glycerides into mono-glyceride and fatty acids, (III) the formation of mixed
micelles with hydrolysis products and bile salts and ultimately absorption through the
intestinal wall (Carey et al., 1983). The lipid digestion process has been exclusively
described for tri-glycerides. However, there is little information on the fate in Gastrointestinal (GI) lumen of lipids such as propylene glycol esters of fatty acids,
polyglycerol and polyethylene glycol esters.

Micelle formation of lipolytic products with bile salts is the crucial step that enhances
drug solubilization and absorption. The total solubility of certain drugs is proportional
to taurocholate concentration, a major bile salt in the small intestine. A linear
relationship was shown between solubilization and logP of steroids, cyclosporine A,
griseofulvin (Mithani et al., 1996). A detailed discussion of the lipid digestion process
and its impact on drug absorption from the gastro-intestinal tract can be found in other
reviews (Eldem and Speiser, 1989; Embleton and Pouton, 1997; Humberstone and
Charman, 1997; MacGregor et al., 1997).
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The nature of lipids used in the formulation can affect the lipolysis process. The in

vitro lipolysis process can be used to elucidate the effect of lipids on lipolysis. The
details of the process are described in section 6.2.2.

The nature of oil as an influencing factor on absorption ofSEDDS has been discussed
(Craig et al. 2000; Gershanik and Benita 2000). The fatty acid chain length directly
influences lipolysis. The long-chain fatty acids are more inhibitory than the mediumchain ones (Bernback et al., 1987; Hutchison, 1994; Zangenberg et al., 1998; Olbrich
and Muller, 1999; Lacy et al., 2000). The results in Fig.6 show that the shorter chain
length allows more rapid lipolysis among tributyrine, MCT (Miglyol 812) and LCT
(soybean oil) (Hutchison, 1994). Lipase enzyme is active only at interface. The greater
the interface the higher the lipase activity is. Therefore, the extent of lipolysis is very
low for triacetin, this is because it is miscible with aqueous medium so that no
oil/water interface can be formed. The comparison study of in vitro lipolysis between
medium chain and long chain triglycerides quantified by titrimetric, highpreformance
thin-layer chromatography (HPTLC) and ultracentrifugational techniques (Sek et al.,
2002) showed that the rate and extent of digestion of the medium chain triglycerides
was greater than long chain lipids and independent of bile salt concentration.

The surfactants have also important effect on lipolysis. Hydrophilic surfactants such as
Brij 96 (polyoxyethylene 10 oleoyl ether), Tween 80 (polysorbate 80) and Cremophor
RH40 (polyoxyl 40 hydrogenated castor oil) that have HLB value more than 10
inhibits lipolysis while lipophilic ones such as Span 20 (sorbitan mono-laureate) and
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Crill 4 (sorbitan mono-oleate) that have HLB less than 10 do not. This inhibitory
effect with hydrophilic surfactants can be minimized by adding lipophilic cosurfactants like medium chain mono-/di-glycerides to the formulation of interest. In a
recent US Patent (Lacy et al., 2000), it was found that transesterification products of
polyoxyethylene glycol with glycerol esters of capric and caprylic acids, do not inhibit
the in vivo lipolysis of digestible oils. Labrasol (glyceryl caprylate/caprate and PEG
caprylate/caprate) and Softigen 767 (PEG-6 caprylic/capric glyceride) with HLB
values of 14 were given as examples hydrophilic surfactants that do not have
inhibitory effect on lipolysis.

A rapidly digested lipid would promote maximum drug absorption (Hutchison, 1994).
For example, when MCT and LCT have been compared for the absorption of vitamin
E, MCT enhanced intestinal absorption of vitamin E (Gallo-Torres et al., 1978).
However, this effect can not be generalized. CyclosporineA absorption, in contrast to
vitamin E, was higher in LCT than in MCT (Behrens et al., 1996; Renner et al. l 988a,
b). This difference was interpreted as the result of formation of mixed micelles which
occurs during the digestion.

Fluidity and volume of the lipid can affect the gastric retention as it was shown in the
absorption ofSL-512, an anti-inflammatory agent, (Yamahira et al., 1978) and
Phenytoin (Shinkuma et al., 1985). Medium chain tri-glyceride, medium chain monoglyceride, com oil and N-methylbenzyllinoleamide (MBLA) has been investigated as
model lipid vehicles. The solubility of SL-512 was found to be 0.5, 4.2, 0.3 and 2.2%
\
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(w/v) in each vehicle, respectively. Even though, MCM provided the highest solubility
ofSL-512, it has not provided the highest serum level and gastric emptying time. It
was concluded that serum level and gastric emptying time of SL-512 was correlated
with fluidity of the lipids.

Gastric emptying was also affected by the chain length of fatty acids (Hunt and Knox,
1968). Fatty acids with 12-18 carbon atoms slowed down gastric emptying more than
those with up to 10 carbon atoms. C 14 (myristate) was the most effective one.
The effect of chain length of fatty acid of the lipid vehicle on formulation design and
the bioavailability ofHalofantrine (Hf) has been stuided (Khoo et al., 1998). The
solubility of Hf was enhanced by increasing the proportion of Captex (MCT) for the
medium-chain glyceride formulations based on Captex/Capmul (MCM) of
combinations. However, this approach led to less efficient emulsification. A 2: 1 (w/w)
ratio of Captex to Capmul provided a good balance between drug loading and efficient
emulsification. Hf was less soluble in long-chain glycerides compared to the medium
chain ones. Better emulsification was obtained with the formulations that contained
medium-chain glycerides. The authors observed a trend towards higher bioavailability
of the drug with the long-chain tri-glyceride formulations compared with medium
chain glyceride formulations in the beagle dogs. Such anomalous findings apparently
based on differences in intra-luminal processing of the medium- and long-chain
glycerides where the bile salts and the formation of mixed micelles can influence
absorption.
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Lipid digestion products pass across an unstirred water layer (UWL) in the small
intestine. Within the UWL an acidic microclimate aids micellar dissociation so that
monomers pass passively across the brush-border membrane. For long-chain fatty
acids passage across the unstirred water layer is rate limiting, whereas passage of
short- and medium-chain fatty acids is limited by the brush-border membrane
(Thomson et al., 1993).

5.2. Lymphatic absorption
Once the lipolysis products, fatty acids and mono-glycerides, are taken up by
enterocytes, a re-synthesis of the fatty acids and monoglycerides takes place in the
endoplasmic reticulum Together with cholesterol, phospholipid and proteins,
lipoproteins are synthesized. Lipoproteins are characterized as high density
lipoproteins (HDL), low density lipoproteins (LDL), very low density lipoproteins
(VLDL) and chylomicrons. Among all these, chylomicrons are the most abundant in
the intestine cells. They contain the largest amount of tri-glycerides and they are the
largest in size. Since they cannot be taken up by the blood capillaries because of their
size, they enter the lymph capillaries (Tso, 1985; Nijs, 1987; Porter and Charman,
1997). Absorption of a drug through lymphatic system escapes first-pass effect.
In order to incorporate a drug in the tri-glyceride core of the chylomicrons, the drug
must be lipophilic. Probucol, lipophilic vitamins and halofantrine are the most
commonly used model drugs to investigate lymphatic absorption. A lipid used in
lymphatic delivery is important to determine the extent of lymphatic drug transport.
The type of lipid, their degree of saturation, chain length and physical state play an
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important role in lymphatic transport of drugs. LCT lipids are more favorable for the
lymphatic absorption than MCT. Fatty acids containing 14 or more carbon atoms are
considered to be taken up in the lymph, and those containing 8-12 carbon atoms enter
the systemic circulation through the portal vein (Armstrong and James, 1980).
The effect of different oils on the absorption of probucol has been studied in rat (Palin
et al., 1984). The plasma concentration ofprobucol was determined following its
administration in arachis oil (LCT), Miglyol 812 (MCT) and liquid paraffm. The total
absorption of the drug from lymphatic and portal system was significantly greater for
arachis oil formulation than with the other two aforementioned vehicles. The literature
also cites the reverse effect: The lymphatic and portal transport ofretinol (vitamin A)
in unanesthetized rats (Hollander, 1980) demonstrated that addition of short-chain
fatty acids to the infusate did not change the appearance rate of vitamin A in the bile
or lymph. Lymphatic uptake rate of vitamin A peaked following the addition of
medium chain fatty acids to the infusate. Addition of long-chain unsaturated fatty
acids, oleic, linoleic and arachidonic to the infusate inhibited the lymphatic appearance
of retinol as the chain length and degree ofunsaturation increased. The absorption rate
ofretinol in the bile was increased significantly when long-chain polyunsaturated fatty
acids, linoleic and arachidonic acids, were added to the infusate. This indicated that
polyunsaturated fatty acids also shifted the exit of vitamin A from the lymphatic to the
portal circulation. The preferential transport of the polyunsaturated fatty acids into the
portal circulation may also shift the transport of vitamin A into the portal circulation
by a co-transport mechanism.
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In another study with rats, three retinoids, namely isotretinoin, etretinate and
temarotene, have been used to investigate the effects of solubility and lipophilicity on
lymphatic uptake after oral administration in each of three oily vehicles, cottonseed
oil, Miglyol 812 and linoleic acid (Nankervis et al., 1996). Lipid solubility increased
with increasing partition coefficient of the retinoid. However, the rank order of
increasing lymphatic uptake from each of three oils shows an inverse relationship with
solubility of the retinoid in each oil. The reason was explained as follows; the retinoid
is likely to escape from the dosing vehicle before passing across the diffusional barrier
of the unstirred water layer in the gut. It is related to the solubility of the retinoid in the
oil. The easier the diffusion of a drug into the intestine, the more thermodynamically
favorable it will be for the retinoid to partition out of the oil.

The animal model used is important in studies related to lymphatic absorption. Rat is a
commonly used animal model to investigate lymphatic absorption of drugs. The
physiological state of the animal is also important. The effect of type of lipid and
formulation on lymphatic transport ofHalofantrine (Hf) has been studied in the
conscious and the triple-cannulated anesthetized rat model (Porter et al. 1996a,b). It
was found that the lymphatic transport ofH£ in conscious rat was independent of the
type of lipid (triglyceride or fatty acid) and the type of formulation (micellar or regular
solution). On the other hand, the lymphatic transport of Hf in anesthetized rat was
dependent on the type of formulation (micellar, emulsion and solution). It was
proposed that the lipid vehicle effects in anesthetized rat model reflected the lack of

20

gastric processing by preduodenal lipase and the shear action of the stomach that
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presents in the conscious rat model.

The degree of unsaturation of lipid was also reported as a factor on the absorption of
drug molecules (Craig et al. 2000). The effect of unsaturation on intestinal lymphatic
drug absorption has been investigated. The lipoprotein fractions were monitored in
mesenteric lymph following intraduodenal administration of arachis oil and fatty acids
such as oleic, linoleic and linolenic to rats. It was shown that the greater the degree of
unsaturation of the fatty acid, the more rapid the onset of chylomicron synthesis as
indicated by more lymphatic absorption of the fatty acid (Renner et al., 1986; Cheema
et al., 1987). However, absorption of halofantrine was largely independent on
triglyceride unsaturation in a conscious rats (Holm et al., 2001 ).

Lymphatic uptake was also affected by isomers oflipid used. The effect of elaidic (9cis) and oleic acids (9-trans) on lymphatic uptake studied showed that oleic acid
exhibited higher lymphatic recovery rate compared to elaidic acid (Bernard et al. ,
1987).

6. CHARACTERIZATION OF LIPID BASED FORMULATIONS
Lipids enhance bioavailability for poorly soluble drugs. However, they are challenging
to work with because of their physical complexity. It is imperative to use a technique
that does not alter any physico-chemical properties of a lipid-based system. Methods
used for characterization of SEDDS and SLN were summarized by Gershanik and

l,
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Benita (2000) and Muller et al. (2000), respectively. In this review, more detailed
techniques are cited from the literature as well as from our experience for lipid based
delivery systems.

6.1. Formulation and Stability Evaluations:
Thermal and particle size analysis are the common methods that can be used to
evaluate formulation factors such as HLB, concentration of the components and
processing conditions and stability.

6.1.1. Thermal Analysis:
Differential Scanning Calorimeter (DSC) is the most commonly used thermal analysis
technique for characterization of lipid based systems. Some of the lipid vehicles are
solid or semi-solid, therefore formulations containing such vehicles are processed at
temperatures higher than room temperature. Therefore, it is important to characterize
the system with thermal analysis before the formulation process.

DSC analysis will be useful to determine possible interaction between drug and lipid
vehicle especially in solid dispersions. It can be helpful to construct a phase diagram
of the drug of interest versus temperature. Solid dispersions ofUC-781, an antiviral
agent, with Gelucire 44/14 and PEG 6000 have been characterized using DSC.
Melting points peaks were used to construct the phase diagram for solid dispersions.
Based on these diagrams, no eutectic mixtures were observed. Phase diagrams of solid
dispersions and those of physical mixtures were similar suggesting that there was no
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significant chemical change or interaction between the drug and PEG 6000 or Gelucire
44114. It was also showed that based on DSC data, the drug can be dissolved up to a
concentration of25% (w/w) in the liquid phase in PEG 6000 and Gelucire 44114
(Damian et al., 2000).

DSC can be a useful tool in determination of stability oflipid based systems. The
thermal behavior of stored different types Gelucires has been studied using DSC to
examine the relationship between preparation condition and stability (Sutananta et al.,
1994). Based on DSC results, it was concluded that the thermal traces observed during
storage are associated with the segregation or recombination of the Gelucire
components into different microscopic regions within the sample, rather than
polymorphic changes. They also conducted tensile strength measurements indicated
that the strength of Gelucires changed during storage. Modulated DSC has been
utilized in softgel capsules to screen the variables such as temperature and humidity
influencing the hardness of gelatin capsules (Nazzal and Wang, 2001). The gelling
mechanism that occurred in solid lipid nanoparticles that contains Compritol was
investigated using DSC (Freitas and Muller, 1999). The results showed that the
crystallization occur during gelation. However, if the lipid based system is liquid, this
kind of stability problem may not be detected by DSC (unpublished data). Therefore,
it can be said that DSC analysis is more useful for solid based lipid systems.

6.1.2. Particle size analysis:
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Most lipids are either in emulsion/microemulsion form or they can form an emulsion
upon mixing with gastric fluid (self-emulsifying systems). Droplet or particle size will
influence performance of the ultimate dosage form. Therefore, particle size analysis is
an important analytical tool in characterization of lipid based delivery system. There
are number of techniques which are available to measure the particle size. These
include optical microscopy, scattering methods such as light scattering and photon
correlation spectroscopy and electron microscopy. Scattering methods are mostly
commonly used since they cover a wide range particle size (from 2nm to 2 mm).

Particle size measurements provide a quick assessment in comparison of emulsion
systems. For example, the efficiency of self-emulsification by measuring the rate of
emulsification has been studied by monitoring the relative intensity of light scattered
by dispersion and particle size distribution of resulted emulsion using light microscopy
and a Coulter Nano-Sizer (Pouton, 1985a). The mixture ofMiglyol 812 (medium
chain tri-glyceride) or Miglyol 840 (propylene glycol ester of caprylic/capric acid)
with the surfactant Tween 85 (polysorbate 85) provided more efficient selfemulsification system than the mixture liquid paraffin or oleic acid with the surfactant
Tween 85. It was concluded that the Coulter Nano-Sizer provided a quick, noninvasive technique for comparing the mean particle sizes of resultant emulsions but
was inappropriate for sizing all self-emulsifying systems. It was shown that the
determination of particle size with light scattering is more important than comparison
of emulsification rate. Light scattering has been used to measure the emulsification
rate to explain the mechanism of the spontaneity of self-emulsifiable oils. The
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mechanism was explained by liquid crystal formation and it was concluded that
spontaneity was dependent on the nature of the material used in the system (Groves
and Mustafa, 1974). The mechanism of action for self-emulsified systems consisting
ofTagat TO (ethoxylated glycerol tri-oleate) and Miglyol 812 (medium chain
triglyceride) has been also studied using Low Angle Laser Light Diffraction for the
emulsions with droplet distribution above 1 µm (Wakerly et al., 1986). Quasi-elastic
light scattering was used for investigations of submicron dispersions. Ternary phase
studies showed a specific region of lamellar liquid crystal dispersed in the isotropic
phase of solubilized water.

The particle size measurements can be useful to characterize the factors such as HLB
of surfactant, type and concentration of co-surfactants affecting the efficacy of selfemulsifying oral delivery system. Such study has been conducted using selfemulsifying formulations containing surfactants (Spans and Tweens) with different
HLB values (4.3 to 16.7), co-surfactants (mono-glycerides) with varying fatty acid
chain length (Cs to C 1s) and vegetable oils (peanut, soybean and saffiower oil) with
different fatty acid composition (Cs to C1s ). The system was characterized using
dissolution test and particle size measurements (Bachynsky et al.,1997). It was
concluded that a surfactant with an HLB in the range of 11-15 at 5% concentration and
a co-emulsifier consisting of a monoglyceride of caprylic/capric acids at 17%
concentration were most effective in a formulation having good self-emulsifying
properties in terms of particle size and satisfactory dissolution characteristics of an
aratinoid model drug used.

25

(

One should be aware of that using laser diffraction requires dilution of the sample that
may alter the properties of self-emulsifying systems. Therefore, when the particle size
of the sample is above 1000 nm, which is the upper limit of dynamic light scattering,
electron microscopy may be used.

6. 1. 3. Other methods

X-Ray diffraction can be used to monitor any polymorphic changes and to detect
possible lipid-vehicle interactions along with FT-IR (Tandon et al., 2001). Low
frequency dielectric spectroscopy (LFDS) has been used to elucidate the mechanism
of self-emulsification. It was shown that self-emulsification with Imwitor 742 or
Labrafil M2125 CS and Tween 80 occurs via liquid crystal formation depending on
surfactant/oil ratio. It was also shown that LFDS is a useful technique to examine the
individual components in order to investigate the effects of drug inclusion. Surface
tension and particle size measurements were also conducted in order to determine the
effect of drug concentration (Craig et al., 1993a and b, 1995). Refractive index,
conductance and density measurements were conducted to compare the water-in-oil
microemulsions containing long- versus medium chain glycerides (Constantinides and
Scalart, 1997). Rheological investigations and NMR can be used to investigate the
effect of drug loading in MCM (Dumanli et al., 1999). In this study it has been shown
that beyond a certain concentration, the solution reaches a saturation level causing a
change in the slope of concentration vs. zero-shear viscosity and particle size (Fig 4).
The effect of drug loading has been further investigated with NMR showing that as the
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concentration of the drug in MCM increased, the line-widths of drug broadened while
line-widths of MCM remained same.
Zeta potential measurements can help to evaluate physical stability of dispersed lipid
based systems and charged lipid-based formulations (Washington, 1996; Gershanik
and Benita, 2000). Freitas and Muller (1998) studied the gelation mechanisms seen in
aqueous dispersions of solid lipid nanoparticles consisting of 10% Compritol and
1.2% Pluronic F68 by measuring zeta potential of the system. The possible
mechanisms of gel formation are explained as the structural changes of the lipid phase
leading to zeta potential reduction and particle growth. Recently, positively charged
self-emulsifying formulations were developed by Gershanik et al. (1996 and 1998) to
enhance the interaction with mucosal surface and increase cellular uptake. Zeta
potential measurements were conducted to characterize such systems, to investigate
the effect of progesterone incorporation on the charge of the formulation and to show
that the enhanced electrostatic interactions of positively charged droplets with rat
intestinal mucosa} surface are responsible for the uptake of cyclosporine A.

6.2. In vitro/in vivo correlation (IVIVC)
6. 2.1 Dissolution studies

Dissolution testing for poorly soluble drugs requires different media than those
normally used for water-soluble compounds. The incorporation of surfactant into
dissolution media was found useful (Serajuddin, 1988; Roman, 1999; Dressman and
Reppas, 2000). The dissolution ofUC-781 , an inhibitor of HIV-1 replication and a
poorly soluble drug, has been carried out in aqueous polysorbate 80 solutions (Damian
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et al., 2000). The dissolution of physical mixtures and solid dispersions of the drug
compared with PEG 6000 and Gelucire 44/14 showed that the drug release from
Gelucire 44/14 was higher than from physical mixture and PEG 6000. It has been also
shown that the micelle is sensitive to impurities and electrolytes influencing size,
loading capacity, solubility and dissolution rate (Wasan, 2001). The type of surfactant
used in dissolution media is important since it may interact with the capsule shells as
in the case of sodium lauryl sulfate (SLS), an anionic surfactant that may interact with
cationic charges of gelatin at gastric pH (Pillay and Fassihi, 1999). These interactions
may retard the disintegration of the shell. Therefore, two-phase dissolution test method
has been proposed for the poorly soluble compounds by Grundy et al. (1997a, b). The
test system was used as modification of the USP XXII Apparatus 2. The important
feature of this system is containing lower phase that has dissolution medium of750
mL SIF and upper phase that has dissolution medium of250 mL n-octanol. Improved

in vivo-in vitro correlation was demonstrated with two phase dissolution test by
employing Nifedipine gastrointestinal therapeutic system (GITS). The test was used
for dissolution studies oflipid-filled capsules employing Nifedipine as a model drug
(Pillay and Fassihi, 1999).

Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after
oral administration by RRSBW distribution, known as the Weibull distribution,
showed that prediction of plasma profile was possible in seven out of eleven classes
(Nicolaides et al., 2001). In this study, it has been also shown that the plasma profile
of a lipophilic drug can be predicted with appropriate in vitro dissolution data,
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provided that the absolute bioavailability of the drug is known and the drug has
dissolution limited absorption.

6. 2. 2. In vitro lipolysis

A physiologically representative medium should be used to establish in vitro lipolysis.
For this purpose, the media can be simulated intestinal fluid containing 50 mM Trismaleate buffer (pH=6.5), 5m.M CaCl.2H20, 150 mM NaCl, 8 mM sodium
taurocholate and 1.5 mM lecithin. Lipase solution should be added according to
required enzyme activity (20 TBUs per mL of lipase-colipase is recommended).
Lipolysis starts when the enzyme solution is added to tri-glyceride emulsion. The
reaction can be followed by monitoring fatty acid generation via continued titration
with pH-stat. (Hutchison, 1994; Carriere et al., 1997; MacGregor et al., 1997;
Zangenberg et al., 2001 ). Attention should be given to the surfactant that may be
present in tri-glyceride emulsion because most of the surfactants used in lipid
formulation inhibit lipolysis. There are not many published studies that correlate in
vitro lipolysis and in vivo results. Only preliminary results were given for progesterone

with good in vivo correlation (MacGregor et al., 1997) whereas no IVIVC was
established for cyclosporine. Olive oil as LCT and Miglyol 812 as MCT have been
compared for cyclosporine intestinal absorption both in vitro and in vivo (Reymond et
al., 1988a, b). An in vitro lipid digestion method established was used to compare
LCT and MCT in terms of the drug partitioning into aqueous phase. It was
demonstrated that lipid digestion promotes the partition of the drug in the aqueous
phase for MCT, whereas for olive oil presence of lipolysis products in the aqueous
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phase after digestion decreases the distribution of Cyclosporine into this phase.
However, their in vivo results showed that drug permeation is higher with LCT.
Digested vehicles promoted the absorption compared to the non-digested ones. It was
concluded that in vitro phase quantification could not simulate in vivo absorption
events.

6.3. Absorption mechanisms
Increased absorption mechanisms with lipids involve increasing drug
solubility/dissolution, changing gastric and intestinal transit time, stimulation of bile
flow and increased intestinal permeation (Muranishi, S., 1985; Aungst et al., 1993,
1996). Reduced particle/droplet size can be another reason that lipid-based
formulation can provide increased absorption. These mechanisms can be elucidated
with measuring dissolution test and particle size of the formulation, using cell
monolayers and imaging techniques. Zeta potential measurements can also be useful
to study the mechanism of charged lipid based systems (Gershanik et al, 1998).
Particle size measurements can be used to show the mechanism of increased
bioavailability of certain drugs. For example, enhanced the bioavailability of poorly
soluble Cyclosporine A has been studied in o/w microemulsions consists of
capric/caprylic triglyceride as an oil(Captex 355), polyoxyethylated castor oil
(Cremophor EL™) as a surfactant, TranscutolrM as co-surfactant and saline (Gao et al.,
1998). It was concluded that the enhanced bioavailability of Cyclosporine A loaded in
this microemulsion system was due to the reduced droplet size of microemulsion
systems.
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Physicochemical interactions between the self-emulsifying system and intestinal
mucosa can also affect drug absorption. The interaction of a self-emulsifying lipid
drug delivery system with the everted rat intestinal mucosa has been demonstrated as a
function of droplet size and surface charge (Gershanik et al., 1998). A positively and a
negatively charged self-emulsifying system was prepared with ethyl-oleate and
oleylamine using Cyclosporine A as a lipophilic model drug. Transmission electron
microscopy has been used to measure the particle size of the self-emulsifying systems.
They found that the enhanced electrostatic interactions of positively charged droplets
with the mucosa} surface are mostly responsible for the preferential uptake of
Cyclosporine A from the positively charged droplets as compared to negatively
charged droplets. Positively charged self-emulsifying oil formulation containing
Tween 80, benzyl alcohoL ethyl oleate and oleylamine also elicited the highest and
most satisfactory absorption profile for progesterone (Gershanik and Benita, 1996).

6. 3.1. Imaging techniques

Imaging techniques such as scintigraphy, ultrasound and magnetic resonance imaging
can be used to get detailed visualization of transit absorption oflipids in the body. The
effect of oleic acid on human ileal break was determined by measuring the transit of
radio-labeled tablets by gamma scintigraphy in volunteers (Dobson et al., 1999). It
was shown that oleic acid activated the ilea} brake that slowed the transit of tablets
through small intestine. Readers can refer to a review by Wilson et al. (1997) for
more details about imaging techniques.
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6. 3. 2. The use of cell monolayers

I
l

The Caco-2 cell, derived from a human colorectal carcinoma, has been used
extensively to study the permeation of drug compounds. It especially useful to predict
the intestinal absorption mechanisms. Mechanisms of lipid uptake and metabolism
have been studied in the nutrition area using Caco-2 cells as a model. This information
can be applied to study lipid based drug delivery. It has been reported that many of the
biochemical and metabolic features of lipid processing in vivo have been shown to
exist in Caco-2 cells (O'driscoll, 1998). These features include fatty acid uptake,
esterification and triglyceride formation, cholesterol absorption, esterification and
synthesis, synthesis and secretion of lipoproteins, expression of P-glycoproteins (PGP) and CYP3A-like cytochrome P450 activity. However, it is important to be aware
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of fact that there are also some differences such as no fatty acid binding proteins
(F ABP) in Caco-2 cells.

Efficacy and toxicity screening of various enhancers has been studied using Caco-2
cell (Quan et al., 1998). The findings indicated that the effectiveness of absorption
enhancers in the Caco-2 monolayer system was similar to an in vivo rat system. The
Caco-2 cell model was also used to investigate the charge dependent interactions of
positively charged SEOF with human intestinal epithelial cells (Gershanik et al.,
2000). It was shown that the positively charged emulsions affected the barrier
properties of the cell monolayer at high concentrations and reduce the cell viability.
However, no detectable cytotoxic effect was observed with following dilution.
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The effects ofCapmul MCM on physiological properties of rabbit ileum and distal
colon, including active ion transport, trans-epithelial resistance and passive
permeability have been investigated in vitro (Yeh et al., 1994). It was found that
Capmul MCM inhibited active ion transport.

7.

CONCLUSIONS

Lipids can play a significant role in improving absorption of poorly soluble drugs.
Their physicochemical and physiological aspects should be well defined.
Physicochemical aspects including characteristics of lipids and its affect on drug
solubility and stability should be studied. In physiological aspects, understanding the
lipid digestion process will help to design a rational lipid drug delivery systems.
Judicial selection of lipids through knowledge of a lipid's physicochemical and
physiological properties can overcome absorption of poorly soluble drugs. This is
rapidly evolving area and the future of lipid drug delivery system is quite promising.
Certainly, further research on areas like lipid digestion and absorption is desirable.
More mechanistic studies that will include different variety of lipids are needed. The
type of model drugs used in research purpose should be extended to be more

representative and rational. The drug/lipid relationship should be carefully
investigated to design a cost-effective formulation with enhanced bioavailability
together with optimum stability and manufacturability.
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Table 1: Examples of Commonly Used Lipids in Oral Drug Delivery
Table lA: Examples of Fatty Acids Commonly Used in Oral Drug Delivery
Chemical

Chemical Name

Acids

Fonn 11

MP (°C)

HLB

Density 1

IT

Caprylic acid (Cs)

Emery 657 (Henkel)

L

16.5

-

0.8995

2.52

Capric acid (C10)

Emery 659 (Henkel)

L

31.5

-

NIA

NIA

Laurie acid (C12)

Emery 652 (Henkel)

s

43-45

-

NIA

NIA

Myristic Acid (C14)

Emery 655 (Henkel)

s

53-55

-

NIA

NIA

Palmitic Acid (C16)

Emersol 143 (Henkel)

s

60-68

-

NIA

NIA

Stearic Acid (C1s)

Emersol 153 NF

s

64-70

-

NIA

NIA

Crossential 0 94

L

8-10

(Croda)

L

8-10

0.8842

10.44

L

-5
0.8942

11.00

0.9036

9.43

COOH
+:>

\0

Some Physico-chemical Properties*

Names

Structure

Fatty

Examples of Trade

(CH2)n

2

(Henkel)
CH3

Oleic acid (C1s:1)

Emersol 6313 (Henkel)
Linoleic acid (C1s:2)

Crossential L98 (Croda)
Emersol 315 (Henkel)

Linolenic acid (C1s:J)

Crossential LN75
(Croda)

L

-11

-

-Table lB: Examples of Commonly Used Glyceryl Mono- And Diesters
Chemical

Chemical Name

Structure

Examples of Trade

Some Physico-chemical Properties*

Names

Form"

MP (°C)

HLB

Density 1

IT 2

Glyceryl

Glyceryl

CapmulMCMC8 Abitec)

SS

-

5-6

NIA

NIM

mono-

monocaprylate

Imwitor 308 (Sasol)

s

30-34

6-7

1.0132

NIM

di-esters

Glyceryl mono/di-

Imwitor 988 (Sasol)

L

20-25

4 -6

0.9931

1.20

H2C - OH

caprylate

HC - OH

Mono/di-glyceride of

Capmul MCM (Abitec)

L

25-30

5-6

1.0010

NIM

H2C - O COR

caprylic/capric acid

Imwitor742

L

25-30

5-6

Mono-

Glyceryl mono-laurate

Imwitor 312 (Sasol)

56-60

5-6

NIA

NIA

glyceride

Glyceryl

Preciro!ATO (Gattefosse)

s
s

53-57

2

NIA

NIA

57-62

3-4

Imwitor 191 (Sasol)

s
s

66-71

4

NIA
NIA

NIA
NIA

Glyceryl mono-oleate

Peceol (Gattefosse)
Capmul GMO (Abitec)

L
L

-

3
3-4

0.9352
0.9378

3.32
3.58

Glyceryl

Maisine (Gattefosse)

L

-

4

0.9385

3.87

Glyceryl behenate

Compritol 888ATO

s

69-74

2

NIA

NIA

Vl

pa Im itosteara te

0

H2C - OH

Glyceryl mono-stearate

H C 0-COR
H2CO - COR
Di glyceride

Capmul GMS50 (Abitec)

-.....

~-

Table lC: Examples of Commonly Used Triglycerides
Examples of Trade

Some Physico-chemical Properties*

Names

Form11

MP (°C)

HLB

Density 1

IT2

I

Crodamol GTCC (Croda)

L

-

-

0.9325

15.20

Capric triglyceride

Labrafac CC (Gattefosse)

L

-

1

0.9331

13.96

Triglycerides

Miglyol 810 (Sasol)

L

-

1.5

0.9404

12.06

H2C- O-COR

Captex 300 (Abitec)

L

-

1.5

0.9414

14.76

-

-

0.9354

15.14

Chemical

Chemical Name

Structure
Caprylic

NeobeeM5 (Stepan)
HC- 0-COR

Glyceryl tricaprate

Captex 1000 (Abitec)

s

-

1.5

NIA

NIA

Glyceryl trimyristate

Dynasan 114 (Sasol)

s

55-58

I

NIA

NIA

Glyceryl tripalmitate

Dynasan 116 (Sasol)

s

61-65

1

NIA

NIA

Glyceryl tristearate

Dynasan 118 (Sasol)

s

70-73

1

NIA

NIA

Glyceryl trioleate

Captex GTO (Abitec)

L

-

I

0.9056

16.87

H2CO- COR
V1

........

-Table lD: Commonly Used Propylene Glycol Esters
Chemical

Chemical Name

Structure
Propylene glycol
esters

H3C
HC - 0 COR
H2C - O COR

Propylene glycol
monocaprylate
Propylene glycol
di ca prate
Propyleneglycol
dicaprylatel
dicaprate
Propylene glycol
monolaurate

Examples of Trade

Some Physico-chemical Properties*

Names

Fonn11

MP (°C)

HLB

Density 1 IT 2

Capmul PG-8 (Abitec)

L

-

2-3

0.9372

3.2

Capryol 90 (Gattefosse)

L

-

6

0.9360

5.9

Captex 100 (Abitec)

L

-

2-3

NIA

NIA

Captex 200 (Abitec)

L

-

3

0.9078

11.3

Lauroglycol 90

L

-

5

0.9136

6.7

(Ga ttefosse)

L

-

4

NIA

NIA

E-32238 (Cognis)

L

-

-

NIA

NIA

Emery 2379-U (Cognis)

L

-

-

NIA

NIA

Capmul PG-12 (Abitec)
Vl

N

Propylene glycol
monooleate
Propylene glycol
dioleate

~

Table lE: Commonly Used Polyglycerol Esters
Chemical Structure Chemical Name

Polyglyceral esters

Diglyceryl mono-oleate

Triglyceryl mono-oleate
CH - OH

CH2
HC- OCOR
0-CH
u.
VJ

Names

Form 11

MP (°C)

Capral 2GO

L

-

L

-

s

Density 1

IT2

0.9733

2.66

6.5

0.9756

2.34

-

6.5

NIA

NIA

1.0211

1.59

HLB

Capmul 3GO
(Abitec)

Triglyceryl mono-

Capmul 3GS

stearate

(Abitec)

Hexaglyceryl di-oleate

Capra! 6G20 (Abitec)

L

-

8.5

Hexaglyceryl di-stearate

Plural Oleique

L

-

6

(Gattefosse)

s

-

8.5

H2C
HC-OH
H2C - O-COR

Some Physico-chemical Properties*

(Abitec)

CH2 - 0-COR

H2C-O

Examples of Trade

Capra! 6G2S (Abitec)
Decaglyceryl tetraoleate

Capra! 10G40(Abitec)

L

-

6

NIA

NIA

Decaglyceryl decaoleate

Capra I 1OG100

L

-

3.5

NIA

NIA

(Abitec)

~

Table IF: Commonly Used PEG Esters
Chemical

Chemical Name

Examples of Trade Names

Structure

11

MP (°C)

HLB

Density 1

PEG200 caprylatelcaprate

E-32237 (Cognis)

L

-

-

NIA

esters

PEG200 monolaurate

Emerest 2620 (Cognis)

L

-

9

NIA

COR

PEG200 monooleate

Emerest 2624 (Cognis)

L

-

8

NIA

PEG400 caprylatelcaprate

Softisan 767 (Sasol)

L

-

14

1.0651

CH2

PEG400 monolaurate

KesscoPEG400ML (Stepan)

L

-

13

0.0179

O)n

PEG400 dilaurate

KesscoPEG400DL (Stepan)

L

-

10

0.9786

PEG400 monooleate

Emerest 2646 (Cognis)

L

-

12

NIA

PEG400 dioleate

Kessco PEG 400 (Stepan)

L

-

8.5

0.9690

PEG 1500 lauratelmyristate

Gelucire 44114 (Gattefosse)

SS

44

14

NIA

PEG 1500 palmitatelstearate

Gelucire 50113 (Gattefosse)

SS

50

13

NIA

H

+>-

Form

Poly-ethyleneglycol

0

V'I

Some Physico-chemical Properties*

(CH2

*Our calculations and experimental findings
#

L: Liquid, S: Solid, SS: Semi-solid

'Density measurements (glcm 3 ) were done using Paar Oscillating U-Tube method at 37°C.
2Interfacial tension (IT) (mNlm) against gastric fluid were conducted with Kruss K 12 Tensiometer using the ring method at 3 7°C,
NIM: It could not be measured due to spontaneous emulsification NIA: Not available

-

......

Table 2: Properties of Type I, II, IIIA and IIIB Lipid Formulations Based on Pou ton Classification (Redrawn with the
permission of publisher of ref. Pouton, 1999)

Increasing Hydrophilic Content

...

Type I

Type II

Type IIIA

Type IIIB

Triglycerides or mixed glyceride

100%

40-80%

40-80%

<20%

Surfactants

-

20-60%

20-40%

20-50%

(HLB<12)

(HLB>l 1)

(HLB > l I)

Typical Composition

Hydrophilic cosolvents

-

-

0-40%

20-50%

Particle size of dispersion

Coarse

100-250 nm

100-250 nm

50-100 nm

Significance of aqueous dilution

Limited

Solvent capacity

Some loss of

Significant phase

importance

unaffected

solvent capacity

changes &

V1
V1

potential loss of
solvent capacity

Significance of digestibility

Crucial

Not crucial but

Not crucial

Not required

requirement

likely to occur

may be inhibited

Not likely

---.

-

Table 3. Lipid Systems: Solution and Suspension
Composition of lipid
formulation used

Drug investigated

Purpose of the study

Outcome of the study

Reference

3% (v/v) Phenol red
0. 1N Potassium
salts of saturated
fatty acids
(C2 - C1 s)
Water to make
1000 mL

Phenol red
MW= 354,
oil-soluble model
compound

To seek a relationship
between the chain length of
fatty acids and the slowing of
gastric emptying

Fatty acids from C2 to C IO do not
change gastric emptying time, while
fatty acids with C1 2 to C1 s carbon
atoms delayed in gastric emptying

Hunt and
Knox 1968

SL-512
MW =296.5 ,
anti-inflammatory
agent

To investigate the
relationship between drug
absorption and gastric
emptying of lipid
formulations

Higher viscosity and volume of
lipids ( ~ 100 µL/rat) delayed the
absorption of the drug due to longer
retention time of drug in the stomach

Yamahira
et al. 1978

-

Vl

0\

0.5 % (w/v) solution
of drug in MCT,
MCMandMBLA
0.5% suspension of
drug in com oil

~

Table 3. Lipid Systems: Solution and Suspension (continued)
Composition of lipid
formulation used

Drug investigated

Purpose of the study

Outcome of the study

Reference

1% (w/v) drug solution

SL-512
MW =296.5,
anti-inflammatory
agent

To investigate the absorption
characteristics of the drug in
rats in relation to digestibility
of lipids

Serum level of the drug was found
to be much higher from MCT
(digestible lipid) than from MBLA
(non-digestible lipid)

Yamahira
et al. l 979a

Cyclosporine A
MW=l202,
.
.
1mmunosuppress1ve

To compare the effect of
LCT and MCT on absorption
in conscious dogs

Absorption of the drug was 10 times
higher with LCT than with MCT.
The difference was due to the
formation of mixed micelles which
occurs during digestion ofLCT but
notMCT

Behrens et
al.
1996

Probucol
MW = 516.9,
hypocholesterolemic

To investigate the effect of
lipid vehicles on the
gastrointestinal absorption of
probucol in rats

Digestible oils (Arachis oil and
Miglyol 812) provided higher
plasma concentrations than Liquid
paraffin. Arachis oil provided the
highest plasma and lymph
concentrations

Palin et al.
1983

m:
-

V1
-..J

MCT
MBLA
5% drug (as
solution in ethanol)
qs. to l 00% olive
oil as LCT or
Miglyol812 as
MCT

Unit dose consists of:
100 mg/kg drug and 0.5
mL of one of
following lipid vehicles
Arachis oil ,
Miglyol 812
Liquid paraffin

/

~

-

Table 3. Lipid Systems: Solution and Suspension (continued)
Drug investigated

Purpose of the study

Outcome of the study

Reference

-

To determine the effect of
unsaturation on lipoprotein
fractions in the lymph

The use of fatty acids with greater
unsaturation should be considered in
lymphatic drug delivery because
they increase the onset of
chylomicron synthesis

Cheema et
al.
1987

7.1 % Drug in:
Glyceryl
monooleate

Ubidecarenone
MW= 863,
used in angina
pectoris

To improve the absorption of Bioavailability was same compared
the drug
to the physical precipitate of the
drug

Pozzi et al.
1991

Solution of 3 retinoids
(3mg/mL) in each
vehicle:
Cottonseed oil
Miglyol 812
Linoleic acid

Isotretinoin MW =
300,
Etretinate MW =
354,
Temarotene MW =
304,
used in acne
treatment

To investigate lymphatic
transport of three retinoids in
the rat in terms of effect of
lipophilicity and lipid vehicle

Nankervis
et al. 1996

Composition of lipid
formulation used

-

Vl

00

Oleic acid
Linoleic acid
Linolenic acid
Arachis oil

Lipid solubility increased as log P
increased but lymphatic uptake
decreased as the solubility increased

,-

Table 3. Lipid Systems: Solution and Suspension (continued)
Composition of lipid
formulation used

Drug investigated

Purpose of the study

Outcome of the study

Reference

Unit dose contains:
4% (w/v) Drug
50µL mixture of
oleic acid and
glyceryl monooleate (2: 1 w/w)

Halofantrine
MW= 500.5 ,
antimalarial

To investigate the lymphatic
transport of Halofantrine

Lymphatic transport was evaluated
using micellar, emulsion and
solution formulations. The lipid
solution provided the least intestinal
lymph and plasma uptake of the
drug in the triple-cannulated
anesthetized rat model

Porter et al.
1996 a & b

7.5 % (w/v) drug in
Peceol

Ontazolast
MW =335,
used for asthma

To compare the
bioavailability of the drug as
aqueous suspension,
emulsion and SEDDS

All lipid formulations provided a 1419-fold increase in bioavailability
compared to an aqueous solution.
Lipid solution provided the highest
lymphatic absorption

Hauss et al.
1998

200 mg drug with
MCM in unit dose

Saquinavir
MW = 671,
HIV protease
inhibitor

To compare the powder and
lipid formulation of the drug

Bioavailability of Saquinavir in lipid
is 3 times higher than that of powder
formulation

-

Vl

l.O

Perry &
Noble 1998

~
~

Table 4. Lipid Systems: Micellar Solutions
Composition of lipid
formulation used

Drug used

Purpose of the study

Outcome of the study

Reference

350nM retinal
2.5mM fatty acid (Butyric
acid (C 4 ),0ctanoic acid (Cs),
Oleic acid (C 1s: 1), Linoleic
acid (C 18 :2) or Arachidonic
acid (C204)
5-15mM Sodium taurocholate

Retinal
MW=
286.5,
vitamin A

To seek the influence of pH,
bile and fatty acids on retinal
lymphatic and portal transport

Caprylic acid provided the highest
lymphatic transport whereas
linoleic and arachidonic acids
provided the highest portal
transport

Hollander,
1980

To investigate the effect of
saturated and unsaturated
lipids on the composition of
lymph tri-glycerides in rats

There were no differences in the
size of chylomicrons formed with
saturated and unsaturated lipids
but their clearance rates varied

Renner et
al., 1986

To investigate lymphatic
transport of Halofantrine

Micellar solution provided higher
lymph and plasma concentration
than an emulsion and a solution in
the triple-cannulated anesthetized
rat model

Porter et
al., l 996b

-

-

19.2mM Fatty acid (palmitic,
oleic or linoleic)
19.2 Monoolein
20mM Taurocholate

0\

0

Unit dose contains:
4% (w/v) Drug
50µL mixture of oleic acid
and glyceryl monooleate (2: I
w/w)
4% (w/v) Tween 80
Saline to make 2.88 mL

Halofantrin
e
MW=
500.5,
anti malaria
l

Table S. Lipid Systems: Emulsions and Microemulsions

0\

Composition of lipid
formulation used

Drug used

Purpose of the study

Outcome of the study

Reference

0.0005% (w/v)Vitamin E
5.7% (v/v) Trioctanoin
(MCT) or Triolein
(LCT)
carbohydrate, saline and
proteins

D-a-(5-MethylH) tocopherol
MW =430,
vitamin E

To develop MCT formulation
for Vitamin E and compare
the bioavailability between
MCTandLCT

MCT enhanced the intestinal
absorption because it increased
water solubility of vitamin E

GalloTorres et
al. 1969
and 1978

1% (w/v) micronized drug
I% (w/v) Polysorbate 60
40% (v/v) com oil
water to make 100%

Griseofulvin
MW = 353 ,
anti fungal

To investigate absorption
characteristics of the drug
from o/w emulsions and
suspensions

The bioavailability has been
increased 2.5-fold with
emulsions compared to aqueous
suspension

Carrigan
and Bates
1973

0.334 % (w/w) drug
in glyceryl mono-oleate
emulsion

Danazol
MW = 337.5,
steroid hormone

To compare the
bioavailability of danazol
from an emulsion and a tablet
in human in fed and fasted
state

Emulsion formulation increased
the bioavailability of drug 4fold compare to tablets in fasted
subjects but the differences was
not significant in the fed state.

Charman
et al.
1993

Table 5. Lipid Systems: Emulsions and Microemulsions (continued)
Drug used

Purpose of the study

Outcome of the study

Reference

Cyclosporine A
MW=l202 ,
.
.
1mmunosuppress1
ve

To compare the
pharmacokinetics of a
microemulsion and an
emulsion in human

Microemulsion provided 3
times higher absorption than the
emulsion and reduced the intersubject variability

Mueller, et
al. , 1994

-

4% (w/v) Drug
50µL mixture of oleic
acid and glyceryl monooleate (2: l w/w)
0.2% (w/v) Tween 80
Saline to make 2.88 mL

Halofantrine
MW= 500.5 ,
antimalarial

To compare lymphatic
transport of Halofantrine with
emulsion, solution and
micelle

Emulsion provided higher
lymphatic transport than
solution, lower than micellar
solution

Porter et al.
1996b

Microemulsion of the drug
with various ratios of with
Captex355, ChremophorEL,
Transcutol and saline

Cyclosporine A
MW = l202 ,
.
.
1mmunosuppress1
ve

To compare bioavailability of
an o/w microemulsion with
marketed products,
Sandimmun and Neoral

The bioavailability of the drug
in the microemulsion system
was increased 3.3 and 1.25 fold
compared to Sandimmun and
Neoral , respectively

Gao et al. ,
1998

Composition of lipid
formulation used
-

-

0\
N

Sandimmune- Emulsion
form(25 , 100 mg drug in
com oil , glycerol,
Labrafi1M2125CS and
alcohol)
Neoral- Microemulsion
form ( 15, 30, 60 mg drug
in com oil , polyoxyl 40
hydrogenated castor oil
and alcohol)

------

Table 6. Lipid Systems: SEDDS/SMEDDS
Composition of lipid
formulation used
A range of
concentrations of
benzoic acid were
dissolved in:
30% (w/w) Tween
85
70% (w/w) Miglyol
812

0\
\.;.)

Ternary phase of:
Tagat TO,
ethoxylated
glycerol trioleate,
Miglyol 812
Neobee MS
TagatTO

Drug used

Purpose of the study

Outcome of the study

Reference

Benzoic acid
MW = 122,
model compound

To investigate the inclusion
of a model drug on the
performance of SEDDS

Formulations containing
1.5-2% benzoic acid were
the most efficient.

Pouton, I 985b

To investigate the
mechanism of action of
SEDDS

Self-emulsification was a
result of aqueous
penetration into the liquid
crystal aided by mechanical
dispersion
SEDDS improved the
reproducibility of the
plasma profile in terms of
the maximum plasma
concentration

WIN 54954
antipicornavirus

To develop a SEDD
formulation and compare
the bioavailability with
PEG solution in beagle
dogs

Wakerly et al. , 1986

Charman et al. , 1992

i'.'

Table 6. Lipid Systems: SEDDS/SMEDDS (continued)

0\
~

Composition of lipid
formulation used

Drug used

Purpose of the study

Outcome of the study

Reference

2 and 6% (w/v) Drug
56, 60 and 62%
(w/v) Labrafil M
2125 cs
30% (w/v) Tween
80
3% (w/v) propylene
glycol
5% (w/v) water

L-365,260
MW= 398,
benzodiazepine
derivative

Self-emulsification of the
system with and without
drug was investigated
using LFDS, surface
tension measurements and
particle size analysis

LFDS investigations show
the effect of drug loading on
individual components.
Incorporation of drug
changed the surface tension
of the system and droplet
size of the resulting
emulsion

Craig et al. 1993

5% (w/w) Drug was
formulated in various
extent of PGG, MCM,
PEG-25 glyceryl
trioleate Polysorbate80
and peanut oil/neobee
oil

Ro 15-0778
MW = 304,
Used in acne
treatment

To investigate the ability of
PGG with varying fatty
acid and PEG chain lengths
to produce selfemulsification

SEDDS gave 3-fold greater
AUC than solution, tablet
and capsule of wet-milled
spray dried powder in dogs

Shah et al., 1994

-~,

Table 6. Lipid Systems: SEDDS/SMEDDS (continued)

0\
Vi

Composition of lipid
formulation used

Drug used

Purpose of the study

Outcome of the study

Reference

10% Progesterone
- 25% Tween 80
I 0-50% Benzyl
alcohol
- 2.5-3% Oleylamine
- to 100% Ethyl
oleate

Progesterone
MW=314,
hormone

To develop and
characterize a positively
charged self-emulsifying
oil formulation

Positively charged emulsion
provided the highest AUC among
a PEG 300 solution, a suspension,
ethyl oleate and a negatively
charged emulsion in rats. Further
toxicity studies were
recommended

Gershanik and
Benita, 1996

7.5% (w/v) drug in
mixture of Peceol and
Gelucire 44/14 (either
equal or 2:8)

Ontazolast
MW=335,
used for asthma

To compare the
bioavailability of drug with
an aqueous suspension, an
emulsion and SEDDS

All lipid formulations provided
14-19 fold increase in
bioavailability compare to aqueous
solution. The emulsion and
solution provided better lymphatic
absorption than SEDDS

Hauss et al.
1997

L-683,453
Used in benign
prostatic hyperplasia

To compare the
bioavailability between
aqueous suspension and
SEDDS

SEDDS provided 13.7% increase
in bioavailability compared to the
suspension

Matuszewska et
al. 1996

-

Imwitor 742
Tween 80

Table 6. Lipid Systems: SEDDS/SMEDDS (continued)

0\
0\

Composition of lipid
formulation used

Drug used

Purpose of the study

Outcome of the study

5.66 % (w/w) drug in a
series of selfemulsifying systems
containing Myvacet945 , Captex200,
LabrafacCM-10,
Lauroglycol and
Labrasol
100 mg/mL
Cyclosporine A in
mixture of:
- 25 % (w/w) Tween
80
- 30% ethanol
- 3% (w/w)
oleylamine
- qs.100% (w/w)
ethyl oleate

Ubidecarenone
(CoenzymeQ 1o)
MW= 863,
used in angina
pectoris

To develop and
A two-fold increase in the
characterize SEDDS of Qi o bioavailability was observed
using PGG as emulsifier
compare to tablet formulations
and to evaluate
bioavailability in dogs

Kommuru, et al.,
2001

Cyclosporine A
MW = 1202,
.
.
immunosuppres1 ve

To investigate the
interaction of positively
charged self-emulsifying
oil formulations with rat
everted intestinal mucosa

Gershanik et al. ,
1998

Electrostatic interactions were
responsible for uptake of the drug
from the positively charged
droplets

Reference

Table 7. Lipid Systems: Solid Dispersions/Solutions

O"I

-....)

Composition of lipid
formulation used

Drug used

Purpose of the study

Outcome of the study

Reference

15-45% drug
55-85% one of
the following
vehicles: Gelucire
44/ 14, PEG l 000,
PEG, 1450and
PEG 8000

REV 5901
MW=355,
5-lipoxygenase
inhibitor

To investigate the effect of
vehicle amphiphilicity on
dissolution and
bioavailability in dogs

The dissolution and
bioavailability were higher from
the formulation with Gelucire
44/ 14 than that from PEGs.

Serajuddin, et al.
1988

18% drug
82%
gelucire44/ 14 and
PEG 400 mixture
(6: l)

REV 5901
MW=355,
5-lipoxygenase
inhibitor

To compare the
bioavailability from tablets
and solid dispersions in
human

Solid dispersion with lipid
increased the bioavailability of
the drug 5-fold compared to
tablets because of improved
dissolution rate

Sheen et al. 1991

5 % drug
30% Gelucire
44/14
65% Soya lecithin

Ubidecarenone
MW= 863,
used in angina
pectoris

To compare the absorption
physical mixture, lipid
solution and solid dispersion

Solid dispersion provided the
highest AUC in dogs compared
to physical mixture and lipid
solution

Pozzi et al., 1991

----.,__

Table 7. Lipid Systems: Solid Dispersions/Solutions (continued)
Composition of lipid
formulation used

Drug used

Purpose of the study

Outcome of the study

Reference

Gelucires 43/01 ,
50102, 55/ 18, 50/ 13

Theophylline
MW= 180,
Diuretic,
vasodilator

To investigate the effect of
humidity during storage of
Gelucires using dielectric,
viscosity, thermal and
dissolution studies

Gelucires containing more PEG
esters showed more changes than
those containing more glycerides.
No fundamental explanation was
given for mechanism of dissolution
differences under high humidity for
both

Sutananta et al.
1996

Unit dose contained
350 mg drug in
Gelucire 44/14

DMP 323
HIV protease
inhibitor

To improve the
bioavailability of drug at
high doses

Bioavailability was increased 50%
using semi-solid Gelucire 44/14
formulation compared with the
glycol vehicles

Aungst et al.
1997

3.75% (w/v) drug in
mixture of Gelucire
44/ 14 and Labrasol

Nifedipine
MW = 346,
vasodilator

To develop a new method
for dissolution studies of
lipid-filled capsules for
Nifedipine

Two-phase dissolution system has
been developed and used. It has
been suggested to use in lipid based
formulation as an alternative to
USP method

Pillay and Fassihi,
1999

Solid dispersion of
drug was prepared at
various concentration
with Gelucire 44/ 14
and PEG 6000

UC-781
MW=335.5,
antiviral
thiocarboxanili
de

To prepare and characterize
solid dispersions of the drug
with PEG 6000 and
Gelucire 44/ 14 to improve
dissolution properties

Enhanced dissolution rate was
obtained with solid dispersions
compared with physical mixture
and DSC, X-ray, IR were used in
characterization of the system

Damian et al.,
2000
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Table 8. Lipid Systems: Solid Lipid Nanoparticles

0\
\0

Composition of lipid
formulation

Drug used

Purpose of the study

Outcome of the study

Reference

Mixtures of follows at
different ratios
Dynasan 116
Lecithin
Tetronic 908
Pluronic F 127

-

To investigate the gel
formation of phospholipidstabilized SLN

Gel formed because of
crystallization of melt-homogenized
tripalmitate and it can be prevented
by the addition of co-emulsifier

Westesen &
Siekmann, 1997

Longer the fatty acid chains in the
glycerides provided the slower the
degradation. Cholic acid sodium
accelerated the degradation while
poloxamer 407 slowed down

Olbrich &
Muller, 1999

'

5% one of the lipid
(cetylpalmiate, Dynasan 116
or Dynasan 118)
0.5 % one of the surfactant
solution (Cholic acid
sodium salt, Lipoid E80,
Poloxamer 407 or Tween 80
10% (m/m) Compritol 888
ATO
1.2% (m/m) Pluronic F68
Water to make I 00%

-

To investigate the effect of
surfactant and chain length
of fatty acid on enzymatic
degradation of SLN

To investigate long-term
Crystallization occurred during the
stability of SLN in terms of storage leading gelation
crystallinity of lipid phase

Freitas & Muller,
1999
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Table 9.Lipid Systems: Cubic Phase

Composition of
lipid formulation
used

Drug used

-

Glyceryl
monooleate
(GMO)

-

10% (w/w)
drug in
Glyceryl
monooleate
(GMO)

Griseofulvin

Cefazolin (50 and
200µg/g) and
cefuroxime
(200µg/g) in
GMO

Cefazolin &
Cefuroxime

-.J

MW=352, antifungal
Ibuprofen
MW= 206, analgesic
Propranolol
MW= 259, ~-blocker

0

MW = 454 & 424,
antibiotics

Purpose of the study

Outcome of the study

Reference

To form Cubic phase dipersion
called Cubosome™ and compare
with emulsion and liposome
formulations

Lipohilic drugs incorporated
better to Cubosome than to
emulsion

Engstrom,
1990

To investigate the effect of cubic
phase formed with GMO on
dissolution profiles of druP binding
of drugs to mono-glyceride matrix
systems and the influence of the
addition of drugs on the phase
behavior

The solubility of drugs in monoglyceride and surface tension of
drugs affected the dissolution
profiles and phase transitions.
Above the certain concentrations,
the drugs having good solubility
in glyceryl monooleate
transformed the cubic phase into
an inverted hexagonal phase

Chang and
Bodmeier,
1997

To evaluate the ability of the cubic
phase gel to act as a chemical
stability enhancer

The enhanced stability of both
drugs in GMO cubic phase gel
has been demonstrated

Sadhale &
Shah, 1998

(.

Table 10: Solubility of griseofulvin and nifedipine in lipid/Chremophor EL
mixtures

Lipid vehicle

Lipid/Cremophor
EL ratio (g/g)
10/0

Griseofulvin solubility
(mg/g) (mean± SEM)

Nifedipine
solubility (mg/g)

0.683 ± 0.008

3.359 ± 0.029

Miglyol 810

9/1

0.867± 0.004

4.863 ± 0.043

Glyceryl tri

8/2

1.001± 0.007

10.183 ± 0.087

713

1.578± 0.008

17.940 ± 0.123

6/4

2.249± 0.005

23.702 ± 0.091

515

18.276 ± 0.083
10.273 ± 0.091

caprylate (Cs)

CapmulMCM

10/0

4.235± 0.025
4.031 ± 0.005

Glyceryl

9/1

6.542 ± 0.028

14.368 ± 0.037

8/2

6.696 ± 0.059

16.738 ± 0.047

7/3

6.069 ± 0.032

23.873 ± 0.089

614

6.475 ± 0.048

23.720 ± 0.023

515

5.915 ± 0.019

26.478 ± 0.124

Capmul

10/0

3.292 ± 0.019

3.115 ± 0.111

GMO

9/1

3.127 ± 0.008

8.878 ± 0.094

Glyceryl

8/2

3.776 ± 0.043

11. 758 ± 0.087

713

5.235 ± 0.034

16.456 ± 0.108

614

8.457 ± 0.062

18.591 ± 0.056

515

6.110 ± 0.059

24.825 ± 0.083

Caprol 2GO

10/0

2.275 ± 0.006

3.026 ± 0.037

2-glyceryl

9/1

2.916 ± 0.012

7.055 ± 0.148

mono-oleate

8/2

3.551 ± 0.005

10.221 ± 0.097

713

4.005 ± 0.025

14.657 ± 0.084

614

4.278 ± 0.009

19.548 ± 0.174

515

4.567 ± 0.025

24.143 ± 0.267

monocaprylate (Cs)

mono-oleate
(C1s:1)

(C1s:1)
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TablelO: Solubility of griseofulvin and nifedipine in lipid/Chremophor EL
mixtures (continued)

Lipid vehicle

Lipid/Cremophor
EL ratio (gig)
10/0

Griseofulvin solubility
(mg/g) (mean± SEM)

Nifedipine
solubility (mg/g)

1.386 ± 0.002

3.193 ± 0.099

9/1

1.975 ± 0.015

6.217 ± 0.122

8/2

2.494± 0.008

10.679 ± 0.165

7/3

2.554± 0.005

12.353 ± 0.465

6/4

3.133± 0.018

19.385 ± 0.345

515

3.900± 0.030

24.304 ± 0.655

10/0

3.774 ± 0.018

16.983 ± 0.555

9/1

4.497± 0.028

19.256 ± 0.426

8/2

4. 758± 0.020

23.304 ± 0.457

7/3

5.342± 0.019

27 750 ± 0.589

614

7.883± 0.033

31.226 ± 0.891

515

6.516± 0.186

40.032 ± 0.924

10/0

2.197 ± 0.006

8.118 ± 0.243

Capmul PG-12

9/1

2.376 ± 0.012

10.717 ± 0.094

Propylene

8/2

3.410 ± 0.014

13.287 ± 0.243

7/3

4.250± 0.007

18.792 ± 0.145

614

4. 755 ± 0.026

23.359 ± 0.456

515

6.067 ± 0.043

18.055 ± 0.754

10/0

1.913 ± 0.007

5.068 ± 0.035

9/1

1.658 ± 0.012

8.728 ± 0.216

8/2

2.255 ± 0.020

10.990 ± 0.556

7/3

2.280 ± 0.026

14.683 ± 0.423

614
515

2.929 ± 0.013
4.142 ± 0.044

21.050 ± 0.589
30.176± 0.812

Caprol3GO
3-glyceryl
mono-oleate
(C1s:1)

Capmul PG-8
Propylene
glycol monocaprylate (Cs)

glycol monolaurate (C12)
Capmul PG-18
Propylene
glycol monooleate (C1s:1)
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Figure 2. Effect of HLB on release rate of Ro-0778 (ref. Shah et al, 1994)
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Figure 3. Effect of cooling rate on viscosity of wax based
vehicle at different temperatures (Shah et al., 1996)
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Figure 6. Effect of acyl chain length on the rate of triglyceride lipolysis (Hutchison, 1994)
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SECTION I

OBJECTIVES

a. To evaluate solvent properties the lipids available in the US using two poorly
soluble drugs, nifedipine and griseofulvin.
b. To select most suitable lipids and prepare nifedipine lipid formulation to
evaluate its dissolution properties.
c. To assess the bioavailability of the nifedipine formulations in beagle dogs and
to seek a correlation of in vivo data to that of in vitro test results.

79

(

SECTION II
MANUSCRIPT II
A PRACTICAL APPROACH TO DETERMINE CONTRIBUTION OF
MEASURED AND CALCULATED PHYSICAL AND CHEMICAL
PARAMETERS ON SOLVENT EFFECT OF LIPIDS
I. Dumanli 1• 3 , N.H. Shah2 , W. Phuapradit2 , W. Malick2 and M.S. Kislalioglu 1•
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1. INTRODUCTION
The use of lipid vehicles has generated considerable attention in recent years to
improve the bioavailability of poorly soluble drugs. The well-known effect of food in
improving the bioavailability of many poorly soluble drugs such as griseofulvin,
carbamazepine and danazol is the evidence that lipids can be beneficial to drug
absorption (Charman et al., 1992, 1993, 1997; Humberstone and Charman, 1997).
Lipids can improve the bioavailability of drugs through several mechanisms.
Enhancing the solubility/ dissolution of the drug is one of the commonly observed
effects (Pozzi et al., 1991; Sheen et al., 1991; Charman et al., 1992; Shah et al., 1994;
Matuszewska et al., 1996; Aungst et al., 1997).

Although lipids have the potential for enhancing drug absorption, only few
commercial formulations of lipid-based formulations are available on the market.
These are cyclosporine (Sandimmune™ and Neoral™, Novartis), saquinavir
(Fortovase™, Roche), ritonavir (Norvir™, Abbott) and fat-soluble vitamins. One of the
reasons for rarity of commercially available lipid-based products is the physical
complexity of lipids.

Drug solubility in a lipid is the most important factor in the selection of a lipid as a
vehicle. However, due to their physical complexity such as existing as mixtures,
solubility of drugs in lipids is a poorly understood concept. Formulation scientists
many times select an effective lipid that dissolves a given lipophilic drug by trial and
error. The lipids that are screened for this purpose as routine are given in Table 1. In
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general, the lipids that contain a fatty acid distribution and ester combinations provide
better solubility than purer ones. For example, Capmul MCM that contains caprylic
(Cs) and capric acid (C10) provides better solubility than Capmul MCMC8 that
contains only caprylic acid. Since liquid type lipid or lipid combinations are used in
the oral formulations as routine, solubility studies are limited to oily vehicles.

There are a number of studies to show the effects of the physiochemical properties of
the drug on lipid solubility. The melting point and partition coefficient of the drugs are
the key factors affecting solubility in trioleates (Yamaoka et aL 1983; Patton et al,
1984; Mithani et al., 1995; Alvarez-Nunez and Yalkowsky, 2000 and Larsen et al.,
2002). However, systematic studies showing a relationship between lipid solubility of
a drug and physicochemical properties of lipid are limited. Only Anderson and Marra.,
(1999) reported chemical properties that contributed solvent property of synthetic and
natural oils, tributyrin and tricaprylin. It was shown that as the ester concentration of
the lipid increased, the solubility of an investigational anti-HIV agent in the lipids
used increased. It has been also shown that oils having larger molecular volumes
(ethyl oleate, Miglyol 812 and soybean oil) solubilized testosterone less than the oils
with smaller molecular volumes (ethyl butyrate and ethyl caprylate) (Malcolmson et
al., 1998 and Warisnoicharoen et al., 2000).

In general, solvent properties of lipids depend on the chemical, electrical and
structural effects. The polarity, hydrophille-lipohille balance, ester concentration,
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solubility parameters, surface tension and molecular volume can play a role in their
solvent property.

Polarity of a solvent plays an important role in the solubility. Polar solvents are
capable of solvating molecules through dipole interaction forces, particularly via
hydrogen-bond formation, which is a major mechanism in the solubility of a
compound. Polarity of solvents can be defined by dielectric constant (E), which is an
important property related to the solubility and hydrophilic-lipophilic balance
(Gorman and Hall, 1963 and 1964, Carstensen, J.T., 1971, Cave et al, 1979 and
Rabaron et al. 1993). It has been shown that the solubility ofa solute decreased as the
dielectric constant of solvent decreased (Carstensen et al., 1971, Trivedi et al., 1996).
Therefore, dielectric constants of lipids can be evaluated to predict their solvent
properties.

An understanding of cohesive energy between the drug and the lipid molecules may

help to determine how a lipid will behave as a solvent. Cohesion is result of the
London forces, polar interactions and specific ones like hydrogen bonding (Hansen
and Alan, 1971, Barton, 197 5). The most commonly used approach in quantifying the
cohesion between a solvent and a solute is the solubility parameter,8, which is defined
as the square root of the cohesive energy density, expressed as the energy of
vaporization.

8 =(CED) 112 = (LllivNm) 112

(1)
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Where CED is cohesive energy density ~Ev is the energy of vaporization and V m is
the molar volume.
This parameter may be useful to predict the solvating ability of a lipid or the lipid
mixture. When solubility parameters of lipid and the drug are similar, they are
expected to become miscible (Scatchard, 1931, Small, 1953, Krevelen and Hoftyzer,
1972). Determining the solubility parameter of a lipid vehicle and thereby quantifying
its cohesive energy may offer a solution for screening solvent properties of the lipid
candidates.

There are numbers of indirect and direct methods available that can be used to
determine solubility parameter. The practical methods include vapor pressure or
boiling point determinations, solubility/miscibility measurement in liquids with known
cohesive energy, solution calorimetry, and surface energy measurements.
Theoretically, and more often the group contribution method is used (Fedors, 1974,
Samaha et al., 1990, Subrahmanyam et al., 1996, Hancock et al, 1997, Breitkreutz,
1998, Ohta et al., 1999). According to this calculation, the solubility parameter:

OF= [L:~e/L~v] 112
Where

(2)

~e:The

additive atomic group contributions for the energy of vaporization

~v:The

additive atomic group contributions for the molar volume

In this study, the group contribution method given above (2) was used to calculate the
solubility parameter from knowledge of the structural formula of the selected lipids
and drug compounds. This approach is especially useful in the initial stages of the
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pharmaceutical research and development process, where the properties of a new
chemical entity, which is very often in short supply, can be estimated in light of very
little experimental data. Because of lipid's instability during heating, their boiling
point often can not be obtained. Therefore, Fedor's method appears to be the most
applicable one to calculate solubility parameters of lipids.

The hydrophilic-lipophilic balance (HLB) was developed by Griffin to characterize
the polarity of nonionic surfactants. Most of the lipids used in oral drug delivery have
surface-active properties. For example, Capmul MCM has HLB value of 5-6 like
Spans. Capmul MCM has surface tension of around 26 dynes/cm2 . Like surfactants,
the interaction between a lipophilic drug and the lipid can take place at the
hydrophobic part of the lipid vehicle. HLB of surfactants like nonoxynols was
correlated with their solubility parameters (Samaha and Naggar, 1988, Schott, 1984
and 1995, Poulain et al., 1997). Similarly, such correlation may exist in lipids. If so
this property can be a very useful tool to select a suitable lipid to dissolve a given
drug.

It has been also shown that surface free energy of solids was correlated well with
solubility parameters (Samaha and Naggar, 1990). Therefore, surface tension, defined
as the surface free energy change per unit area increase, can be also a useful tool to
predict solvent property of lipids.
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Saponification value is another important chemical property to predict the solvent
power oflipids. It is defined as the weight of KOH used to saponify the ester and fatty
acids. Therefore, it has been used to earlier obtain ester concentration and correlated
well with solvent power of lipids (Anderson and Marra. 1999).

Most of the commonly used solvents like water, ethanol and methanol are small
molecules. Lipids differ from these solvents in terms of molecular weight and purity.
Lipids like triglycerides are much larger molecules. Therefore, they cannot
accommodate large amount of solute. It has been also shown that the oils with larger
molar volume like ethyl oleate, Miglyol 812 and soybean oil solubilized testosterone
less than the oils with smaller molar volumes (ethyl butyrate and ethyl caprylate)
(

(Malcolmson et al., 1998).

The aim of this study is to seek a relationship among the calculated and measured
properties of lipids (MW, SAP, dielectric constant, HLB, solubility parameter and
surface tension) on estimating the solubility of the selected poorly soluble drugs. The
effect of hydrophilic head (glycerine vs. propylene glycol) and lipophilic tail (fatty
acid chain length) of lipid has been also evaluated. Multiple linear regression (MLR)
used to predict aqueous solubility of various drugs previously (Jorgensen and Duffy,
2002) can be utilized to predict the solubility of lipophilic drugs in lipids. MLR is the
technique of predicting a response by a linear combination of several variables. In this
statistical analysis, the variables that are highly correlated toe ach other should not be
used. Correlation coefficient between the properties given above and the solubility of
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the drugs in lipids and the contribution of each property can be found with MLR. The
predictive ability of the model can be tested by regression coefficient which can be
facilitated with a statistical package like JMP®. Nifedipine and griseofulvin have been
selected as the model lipophilic drugs for this study. Nifedipine (Figure l) is a
pyridine carboxylate and griseofulvin (Figure 2) is benzofuran dione. Both drugs have
similar MW around 350.

2. MATERIALS AND METHODS:
2.1. Materials
2.1.1. Model Drugs
Nifedipine (Figure l) is a calcium antagonist, which is used to treat angina and
hypertension. It is 3, 5-pyridinedicarboxylic acid, 1, - dihydro-2, 6-dimethyl-4-(2nitrophenyl)-, dimethyl ester. It has a molecular weight of 346.34. Nifedipine is
practically insoluble in water (9.5 µg/ml at 25°C) and less soluble in ethanol. It is
also light sensitive and converts to a nitrosophenylpyridine derivative when
exposed to daylight and UV light. Therefore, all nifedipine experiments were
carried out under yellow light.

Griseofulvin (Figure 2) is an antifungal agent (7-Chloro-2', 4, 6-trimethoxy-6'methylspiro[benzofuran-2(3H), 1'-[2]cyclohexene ]-3,4' -dione). It is practically
insoluble in water (18 µg/ml at 25°C) and slightly soluble in ethanol. It has
molecular weight of 352.77. It is a classical example used as a model to study
solubility related problems.
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2.1.2. Lipids
Table I. lists the lipids used in this study. Their fatty acids distribution is also
presented in the same table. The lipids used were limited to the liquid. Selection of
the liquid lipid has been made in such a way that the effect of hydrophilic head
(glyceryl vs. propylene glycol), number of glyceryl groups and lipophilic tail (fatty
acid chain lengths) can be investigated. There was no purification involved; they
were used as obtained so that the findings can be helpful for the formulation
scientists who use these materials as provided.

2.2. Methods

l

2.2.1. Experimental Solubility Determination
The solubility of the drugs in each lipid vehicle and water was determined by
adding an excess amount of the drug into 10 g vehicle and equilibrating the
mixture at 25° ± 0.1°C for 72 hr. The mixture was centrifuged for 10 minutes and
filtered through a 0.45µm filter. The amount of griseofulvin dissolved was
determined by UV spectroscopy at a wavelength of328 nm. The calibration curve
used for calculations is given in the appendix, Figure 1. Nifedipine dissolved was
quantified by an HPLC method. A Hewlett Packard 1050 HPLC system with a UV
detector (A =236 nm) was used. The stationary phase consisted of a micro
Bondapak, C 18 reverse phase column (3.9 x 300 mm, Waters Corp., Milford, MA).
The mobile phase used was acetonitrile: methanol: water (2: 3: 3). The samples
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were diluted with methanol before the run. The flow rate was 1.0 mL/min with 30
minutes of total run time per injection.

A standard solution for Nifedipine (0.1 mg/mL) and lipid vehicles was prepared in
methanol and was run with HPLC. The data acquisition was made using the
software Turbochrome 6.1.1.0.0 (Perkin Elmer Corp, Wellesley, MA). Nifedipine
standard curve for the method is given in the Appendix, Figure 2. HPLC
chromatographs of lipids were also obtained to make sure that they don't interfere
with nifedipine peak. All studies were performed in triplicate and coefficient of
variance (CV) for precision of the experiments was± 2%.

2.2.2. Surface Tension
A Kruss K 12 Tensiometer (Kruss USA, Charlotte, NC) was used to determine
surface tension. The plate method was selected. Lipids were equilibrated and
surface tension was measured at 25°C with platinum plate cleaned with flame.

2.2.3. Density Measurements
The density of lipids was measured to use in molecular volume calculations.
The density of a lipid was determined using a Paar Oscillating U-Tube (Anton
PAAR, Ashland, VA) at 25°C. The instrument was calibrated with water. The UTube was filled slowly with the lipid by making sure that there are no air bubbles.
The display after equilibration was recorded as density (g/cm3).
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2.2.4. FT-IR studies
IR spectra for drugs, vehicle and solution were obtained using a Nicolet FT-IR
with Attenuated Total Reflection (ATR) accessory (Nicolet Analytical, Madison,
WI). The lipid and lipid solution of the drug was added to a sample holder. Solid
samples were diluted in mineral oil. First, the spectra of lipids and the model drugs
were taken (Appendix, Figures 3-15). The spectra of drugs solution in lipids were
also recorded. Omnic software Version 6 (Nicolet Analytical, Madison, WI) was
used to obtain spectra and for subtraction of lipid spectrum from solution
spectrum.

2.2.5. HLB calculation
The HLB value of each lipid vehicle was estimated as follows:

s

HLB = 20 (1--)

A

(3)

Where S is the saponification number of the ester and A is the acid number of the
fatty acid. The HLB ofCapmul MCM (Glyceryl mono-caprylate), for which
S=250 and A= 370, is 20 (1- 250/370) = 6.5.

2.2.6. Calculation of Solubility Parameters
Solubility parameters

U>F ) of lipids and drugs were calculated using the group

contribution method devised by Fedors (Eq. 2)
Using equation (2), calculation of solubility parameter of oleic acid {CH3-(CH2) 6 -

(

(Refer to Table II)
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(2)
In this mode4 the contribution of hydrogen bonding is not included. Therefore,
hydrogen bonding contribution was calculated as:
DH= (5000m!V) Yi

(4)

where mis the number of hydrogen donor and acceptors, and Vis the molar
volume (MW/density)
Total solubility parameter (&r) was calculated by adding hydrogen bonding
contribution (8H) to the Fedor's solubility parameter (8F):

OT

=

(OF2 + DH2

(5)

) Yi

Solubility parameters for griseofulvin and nifedipine were calculated by equation
(5). Griseofulvin has 80 of14.77 (cal/cm3) 1n and nifedipine has~= 17.38
(cal/cm3)w. These findings differ from the calculations that appear in the literature
as 8a= 10.44 and~ =10.75 (Hancock et al, 1997, Squillante et al., 1997) due to
addition of hydrogen bonding contributions.

2.2.7. Refractive Index Measurements and Calculations of Dielectric
Constant
The refractive index (N) of each lipid vehicle was measured at 25°C using Abbe
Mark II Model 10480 Digital refractometer (Sodium light at 589 wavelengths)
(Cambridge Instrument Inc., Buffalo, NY).
Dielectric constant (E) of each vehicle was calculated using the equation (6).
N 2 =c

(6).
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2.3.

Statistical Analyses

In order to evaluate the contribution of all the factors together, a stepwise linear
regression analysis has been selected for multiple linear regression analyses of factors
that affect the solubility of drugs. It is an approach to select a subset of effects for a
regression model and facilitates searching and selecting among many models.
Stepwise regression is used when there is little theory to guide the selection of terms
for a model and the modeler. It can be done with forward or backward elimination
methods. Forward brings in the regressor that most improves the fit, given that term is
significant at the level specified by probability to enter. Backward removes the
regressor that affects the fit the least, given that term is not significant at the level
specified in probability to leave. Backward elimination method has been used in this
study. The correlation coefficient (Rad/) and coefficient for each factor was
determined. The model used for this analysis is as follows:

(7)
Where S is the solubility, ai is the coefficient determined by regression analysis to
maximize R 2, Ci is the factor (one of the physicochemical properties of lipid: MW,
dielectric constant, saponification number, surface tension and solubility parameter), i
is the set of factor and ao is the intercept of the linear regression.

The effect of lipid's lipophilic tail (fatty acid chain length), hydrophilic head (glycerol
or propylene glycol and number of glycerol) has been investigated using single factor
ANOV A. The model used for this analysis:
Sij=µ+fi+Eij

(8)
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Where S is the solubility of the drug, i is the level of each factor: The factor lipophilic
tail had 3, glyceryl vs. propylene glycol had 2 and number of glycerol had 3 levels, j is
repetition (solubility experiments were conducted in triplicates),µ is mean,
effect of treatment and

E

r

is the

is the random error.

JMP Statistical Software version 4.0.4 (SAS Institute Inc, Cary, NC) has been used for
all analyses. Significance level of 0.05 has been used for the analyses. The models
adequacy has been checked with residual analysis and lack of fit.

3. RESULTS AND DISCUSSION
The saturated solutions of griseofulvin and nifedipine in each lipid when viewed under
a microscope were all crystal free with exception of griseofulvin in glyceryl monooleate (GMO) which probably dissolved slowly by forming liquid crystals, Figure 3.
The FT-IR studies demonstrated no measurable chemical interaction between the
drugs and lipid vehicles. Figure 4 is an example of the FT-IR spectrum for nifedipine
in Capmul Pg-8. Possible interactions of a lipid and the drug may occur through the
hydrogen bonding and the other polar and hydrophobic interactions. However, there is
no changes in the band appearing at 3400 cm- 1 corresponding to hydrogen bond
stretching (0-H), at 1740 cm- 1 corresponding to carboxylic acid and the bands
between 1470 and 1200 cm- 1 which correspond to C-H and 0-H bending. Since there
is no chemical interaction was observed, the interaction between the lipid and the drug
may be the result of London forces or polar interactions.
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The experimental solubility results for griseofulvin in the tested lipids ranged from
0.318 to 4.031 mg/g and the solubility of nifedipine from 0.322 to 16.983 mg/g (Table
III). Glyceryl mono-caprylate (Capmul MCM) was the best solvent for griseofulvin
increasing the solubility 224 times compared to water. For nifedipine, propylene
glycol mono-caprylate (Capmul PG-8) was the best solvent and the solubility was
increased 1790 times as compared to water solubility.

Lipids used were better solvents for nifedipine than for griseofulvin in increasing
solubility because nifedipine has higher lipophilicity with a log P of 4 (Squillante et
al., 1997) compared to griseofulvin with log P of2 (Mithani et al, 1996 and Nelsen et
al. 2001). The solubility values obtained were used to correlate them with solubility
parameter, MW, polarity and surface tension oflipids that are given in Table IV.

The solubility parameter calculated for griseofulvin is OG = 14.77 (cal/cm3)

112

•

Capmul

MCM that has the closest solubility parameter to that of griseofulvin provided the
highest solubility among all lipids used. However, the same correlation could not be
observed with nifedipine. The calculated solubility parameter for nifedipine is oN

=

17.38 (cal/cm3)1!2 and the lipid that has closest solubility parameter is glyceryl monocaprylate/caprate (Capmul MCM;

o=

15.12 (cal/cm3) 112) but the highest solubility is

provided by propylene glycol mono-caprylate (Capmul PG-8). Overall, calculated
solubility parameter appeared to be a poor predictor for the expected solvent effects of
the lipids.
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The comparison of solubility of the drugs and HLB of lipids showed that only the
solubility of griseofulvin correlated well with HLB of the lipids. As the HLB of the
lipid increased, the solubility of griseofulvin increased, Figure 5, with a correlation
coefficient of 0.9014. However, the solubility of nifedipine did not show any
correlation with HLB of the lipids.

Comparing the solubility of drugs against an individual property of the selected lipid
did not show any common correlation. Therefore, stepwise analysis has been
conducted to evaluate overall effects of all variables. The stepwise analysis has been
selected because there are independent multiple variables. The factors included into
analyses are MW, dielectric constant (DC), SAP, surface tension (Sn and solubility
parameter (8). HLB was excluded from the the model because it is calculated using
SAP value. Regression coefficient and significance (p) were evaluated to determine
the weight of contribution of each property of lipids.

Table V shows stepwise analyses steps for prediction of nifedipine solubility and
Table VI for griseofulvin. As it can be seen from the tables, MW, DC, SAP and
surface tension were significant factors for nifedipine (p<0.05). Solubility parameter is
not significant factor (p>0.05) so that it has been removed from the model. On the
other hand, SAP is not a significant factor for griseofulvin solubility while MW, DC,
surface tension are significant factors (p<0.05). From these analyses, the relationship
to estimate the solubility of nifedipine (Snif, mg/g) can be expressed as (Radj2 =
0.8686):
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Snir= -173+ (-0.054)MW + (80.95)DC + (0.056)SAP + (0.52)ST

(

(9)

Where MW is molecular weight, DC is dielectric constant, SAP is saponification
number and ST is surface tension (dyne.cm-2 ).

The relationship to estimate the solubility of griseofulvin (Sgris, mg/g) can be
expressed as: (Radj2 = 0.8187)
Sgris = -24.61 + (-0.0082)MW + (14.14)DC + (-0.14)ST + (0.34)8

(10)

Where MW is molecular weight, DC is dielectric constant, ST is surface tension
(dyne.cm-2) and 8 is solubility parameter ((caVcm3) 112).

The common propertie<> of the lipids that contribute for the solubilit'' of both drugs are

r

MW, dielectric constant and surface tension. The contribution of MW is the highest

I

for both drugs (R2 = 0.7721 for nifedipine and R2 =0.5701 for griseofulvin). However,
the estimates of each property are different between two drugs indicating a major role
of the drug in lipid solubility. Saponification value representative of ester
concentration was not a commonly shared contributor for both drugs as opposed to
previously shown (Anderson and Marra, 1999). Therefore, it cannot be generalized. It
can be a contributor for more lipophilic drugs like nifedipine as opposed to
griseofulvin.

The effect of hydrophilic head (glycerine vs. propylene glycol, number of glyceryl
groups) and lipophilic tail (fatty acid chain length) oflipid has been tested with
ANOVA for both drugs in accordance with the model described in Section 2.3,
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Equation8. The results in Table VII showed that the effect of fatty acid chain length is

(

significant for both drugs (p< 0.05). The solubility of drugs was increased as the alkyl
chain decreased. Also, griseofulvin being more hydrophilic than nifedipine seems to
be more sensitive to and affected from hydrophilic head changes.

4. CONCLUSIONS
In this study, it has been shown that the lipids used improved the solubility of
nifedipine and griseofulvin compared to the solubility of drugs in water. Calculated
solubility parameter was not sufficient to predict the solubility of drugs in the lipids.
Calculated and measured properties of lipids analyzed with stepwise regression
analyses showed that MW, dielectric constant, surface tension are the common factors
that govern the lipid solubility. However, the estimates of each factor were different

(

for each drug indicating that the drug played important role in lipid solubility. Overall
results showed that MW, dielectric constant, surface tension and fatty acid chain
length contribute the solvent action of lipids.
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Table I: Lipid vehicles used in this study
Chemical Name

Trade Names

Fatty acid distribution*

Oleic acid (C1s:1)

Emersol6313 (Henkel)

75 % C1s:1 6% C1s:2 6% C16:2 5% C16
3%Ct4:t 3%C14

2% C1s:3

Glyceryl tri-oleate

Captex GTO (Abitec)

92% C1s:1 4% C1s:2 3% C1s

Caprylic (Cs) I

Miglyol 810 (Sasol)

71% Cs

29% C10

Capric (C 10 ) triglyceride

Captex 300 (Abitec)

67%Cs

33% C10

Mono-and di-glyceride of

Capmul MCM (Abitec)

81% Cs

17.4% C10

Glyceryl mono-oleate

Capmul GMO (Abitec)

80% C1s:1

Diglycerylmonooleate

Caprol 2GO (Abitec)

90%C1s:1 3%C1s 3%C1s:2

Triglyceryl monooleate

Capmul 3GO (Abitec)

90%C1s:1 3%C1s 3%C1s:2

Propylene glycol monocaprylate

Capmul PG-8 (Abitec)

99%Cs

Porpylene glycol mono-laureate

Capmul PG-12 (Abitec)

99% C12

Porpylene glycol mono-oleate

Capmul PG-18 (Abitec)

93%C1s:1 3%C1s 3%C1s:2

Propyleneglycol dicaprylate

Captex 200 (Abitec)

64%Cs

caprylic(C8)/capric(C 10) acid
0

~

4%C16

4%C1s ll%C1s:2

1% Cto

34%C10 2%C6

(C8)/dicaprate (C 10)

* C6: Caproic, C 8: Caprylic, C10: Capric, C12: Laurie, C14: Myristic, Ct4:t: Myristoleic, C16: Palmitic, C 16:1: Palmitoleic, C 18 : Stearic,
C 18 :1 : Oleic, C1 s:2: Linoleic and C1s:3: Linolenic acid

(

Table II: Group contributions to the energy of vaporization and the molar
volume at 25°C for the functional groups of oleic acid
Group

Lie (cal/mo I)

Liv(cm3/mol)

1 CH3

1125

33.5

14CH2

16520

225.4

I COOH

6600

28.5

2--CH=

2060

27

Total

26305

314.4
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Table III: Experimental solubility results for nifedipine and griseofulvin
Lipid vehicle

Emerso l 6313 (Henkel)
Oleic Acid (Cts:1)

Griseofulvin solubility Nifedipine solubility
mg~ (mean± SEM, n=3)
(mean± SEM, n=3)
0.951 ± 0.006
0.3220 ± 0.0269

ma

Captex GTO (Abitec)
Glyceryltrioleate(C1s:1)

0.318 ± 0.015

1.3028 ± 0.0103

Miglyol 810 (Huls)
Glyceryl tri caprylate(Cs)

0.683 ± 0.008

3.3595 ± 0.0292

Capmul MCM (Abitec)
Glyceryl monocaprylate(Cs)

4.031 ± 0.005

10.2733 ± 0.0913

Capmul GMO (Abitec)
Glycerylmonooleate (C1s:1)

3.292 ± 0.019

3.1149± 0.1112

Caprol2GO (Abitec)
Diglycerylmonooleate(C1s:1)

2.275 ± 0.018

3.0264 ± 0.03712

Caprol 3GO (Abitec)
3 glycerylmonooleate (C1s:1)

1.386± 0.002

3.1930 ± 0.0996

Capmul PG-8
Propy leneglyco l
monocaprylate (Cs)
Capmul PG-12
Propyleneglycol
monolaurate (C12)
Capmul PG-18
Propyleneglycol
monooleate (C1s:1)
Captex 200(Abitec)
propylene glycol
dicapry late(Cs)
water

3.774 ± 0.018

16.9831 ± 0.5556

2.197 ± 0.006

8.1186 ± 0.2429

1.913 ± 0.007

5.0682 ± 0.0353

0.817 ± 0.004

4.1052 ± 0.0668

0.018 ± 0.001

0.0095± 0.0005
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Table IV: Calculated and measured properties of lipids used

Lipid

SAP

(cal/cm 3)

0
-.J

HLB

()

Density

MW

(g/cm 3)

112

Molar

Refractive

Dielectric

Surface tension

volume (cm 3)

index

constant

(mN/m) at 25°C

Oleic acid

-

10.54

1

0.8886

282

307

1.4585

2.1272

32.40

Captex GTO

190

10.63

1

0.9123

863

946

1.4685

2.1565

32.78

Miglyol810

340

12.16

l.5

0.9437

495

525

l.4477

2.0958

29.58

CapmulMCM

250

15.12

6.5

1.0022

275

273

1.4508

2.1048

28.2 l

CapmulGMO

165

12.12

4

0.9451

490

518

1.4688

2.1574

31.36

Caprol2GO

141

12.26

5

0.9814

421

429

1.473

2.1697

29.77

Caprol3GO

143

14.29

6

0.9776

494

505

1.4728

2.1691

37.61

CapmulPG-8

300

13.19

5

0.9387

202

215

1.4363

2.0630

29.3

CapmulPG-12

225

12.26

4

0.9183

258

245

1.4444

2.0863

29.53

CapmulPG-18

162

11.44

3.5

0.9096

340

374

1.4592

2.1293

32.15

Captex 200

329

11.82

3

0.9173

328

375

1.4397

2.0727

30.17

SAP: Saponification, HLB: Hydrophille-lipophille balance, MW: Molecular weight, 8: Solubility parameter

(

Table V. Linear regression analysis with stepwise fit for solubility of nifedipine
Stepwise Regression Control
Alpha

0.05

Current Estimates

SSE

DFE

MSE

RSquare

RSquare Adj

Cp

AIC

58.907758

19

3.100408

0.8914

0.8686

4.020048

31.55006

Parameter

Estimate

nDF

SS

"F Ratio"

"Prob>F"

Intercept

-173.23706

1

0

0.000

1.0000

MW

-0.0545075

1

117.7817

37.989

0.0000

Dielectric

80.958237

1

14.02595

4.524

0.0467

SAP

0.05630996

1

38.5523

12.435

0.0023

Surface tension

0.5228523

1

23.83656

7.688

0.0121

1

0.065537

0.020

0.8890

constant

Solubility
parameter

Step History

Step

Parameter

Action

"Sig

Seq SS

RSquare Cp

Prob"
1

MW

Entered

0.0000

418.9455

0.7721

17.824

2

Dielectric constant

Entered

0.0443

22.12014

0.8129

13.057

3

SAP

Entered

0.0457

18.78224

0.8475

9.3117

4

Surface tension

Entered

0.0121

23.83656

0.8914

4.02

5

Solubility parameter Entered

0.8890

0.065537

0.8916

6

6

Solubility parameter Removed 0.8890

0.065537

0.8914

4.02
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Table VI. Linear regression analysis with stepwise fit for solubility of griseofulvin
Stepwise Regression Control

Alpha

0.05

Current Estimates

SSE

DFE

MSE

RSquare

RSquare Adj

Cp

AIC

3.9353886

19

0.207126

0.8502

0.8187

4.2928

-33.3931

Parameter

Estimate

nDF

SS

"F Ratio"

"Prob>F"

Intercept

-24.609009

1

0

0.000

1.0000

MW

-0.0082946

1

7.90434

38.162

0.0000

Dielectric constant

14.1378874

1

2.821204

13.621

0.0016

0.062991

0.293

0.5951

SAP
-0.1443072

1

2.321461

11.208

0.0034

Solubility parameter 0.34747891

1

3.551889

17.148

0.0006

Surface tension

(

Step History

Step

Parameter

Action

"Sig Prob" Seq SS

RSquare Cp

1

MW

Entered

0.0000

14.97806

0.5701

32.51

2

Solubility parameter

Entered

0.0065

3.423615

0.7004

18.596

3

Dielectric constant

Entered

0.0342

1.61624

0.7619

13.084

4

Surface tension

Entered

0.0034

2.321461

0.8502

4.2928

5

SAP

Removed 0.5951

0.062991

0.8502

4.2928
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Table VII. Effect of hydrophilic head (glyceryl/propylene glycol and# of glyceryl group) and lipophilic tail (fatty acid chain
length) on solubility of nifedipine and griseofulvin analyzed by single factor ANOV A
Nifedipine

Lipids

Functional group
i=Level

Factor 1:

Solubility(mg/g)

F ratio

Griseofulvin
p

Solubility(mg/g)

CapmulMCM

10.273

4.031

CapmulGMO

3.115

3.292

F ratio

p

0.3994

0.0950

2207.144

0.0001

I

Glyceryl vs.

1.1993
propylene glycol

0.1918

CapmulPG8

16.983
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Figure 1. Nifedipine chemical structure
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Figure 3: Liquid crystal formed with griseofulvin in glyceryl mono-oleate.
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1. INTRODUCTION

The use of lipid vehicles has generated considerable attention in recent years for
improving the bioavailability of poorly soluble drugs as one of the approaches to
improve their oral bioavailability. One of the advantages of lipids in delivery of poorly
soluble drugs is to improve the bioavailability of drugs by enhancing
solubility/dissolution (Pozzi et al., 1991; Sheen et al., 1991; Charman et al., 1992;
Shah et al., 1994; Matuszewska et al., 1996; August et al., 1997).

Lipid-based drug development phases can be classified as (I) selection of lipid
vehicle/sand design of dosage form, (II) dissolution, product performance and
bioavailability testing. Selection of the best lipid vehicle is one of the important chores
in lipid formulations.

A suitable solvent for the lipid formulation usually contains a lipid and a surfactant.
Depending on the solubility/concentration of the dug incorporated, saturation can
influence the absorption of the drug. A lipid that is suitable for a drug delivery system
must be safe and, therefore, the first requirement for these excipients is to be classified
as GRAS (generally recognized as safe) materials. The potential toxicity of the
surfactant incorporated should be considered carefully especially in chronic use. This
evaluation includes not only the type of the surfactant but also its concentration/dose
(Swenson et al., 1994).
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To optimize the lipid solubility and particularly the release of the drug, addition of a
co-solvent and surfactant/scan be useful. Ratios of the co-solvent, lipid and surfactant
should be optimized to avoid potential precipitation of the drug in the gastro-intestinal
(GI) media. To understand the performance of the formulation in GI media, the lipid,
surfactant, co-solvent and drug combinations can be evaluated upon aqueous dilution
using the phase diagrams (Shah et al., 1994; Constantinides, 1995 and Kim et al.,
2000). Since only few lipids are capable of maintaining the drug in the solution form
in the GI fluid, the surfactant addition may be necessary to maintain a good
dispersibility of the drug.

Based on these facts, the solubility of a drug in a lipid is an important factor in
selection of the lipid as a vehicle. This issue has been discussed earlier by the same
group (Manuscript 2). Although, MW, fatty acid chain length and dielectric constant
were determined as the common contributors to the solvent property of a given lipid,
specific drug - lipid interactions are still important factors.

On the other hand, release of a drug from the vehicle was found to be an inverse
function of its solubility in the lipid system (Armstrong and James, 1980). Therefore,
chemical potential (concentration/solubility) and partitioning of the drug from the lipid
to the immediate aqueous environment should be considered in lipid-based
formulation design.
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HLB plays an important role in the selection of the lipid vehicles in such formulations.
Even though most of the lipids have no surface-active properties, medium chain
mono-glycerides exhibit surfactant properties. HLB provides reliable practical
information about the water miscibility of the lipid and the surfactant. HLB of
polysorbates varied the dissolution ofaratinoid (Bachynsky et al., 1994). Shah et al.
(1994) showed that HLB of the oil surfactant mixtures affected the release property of
a freely oil soluble drug.

Dissolution testing for poorly soluble drugs requires modification of the routinely used
media. Incorporation of a surfactant into the dissolution media improved dissolution of
poorly soluble drugs such as REV5901, UC781 (Serajuddin, 1988; Roman, 1999;
Dressman and Reppas, 2000 and Damian et al., 2000). The mechanism of surfactant
facilitated dissolution of poorly soluble drugs has been reviewed by Crison et al.
( 1996) and summarized as mice Ile-facilitated dissolution. Polysorbate 80, sodium
lauryl sulfate and polyoxyl-35 castor oil are the most commonly used surfactants
added to the medium to improve dissolution of the poorly soluble drugs.

The surfactant concentration selected depends on the critical micellar concentration of
the surfactant and micellar solubility of the drug. The type of surfactant used in the
dissolution medium is also important because of the possible interactions with the
capsule shells as it happens with sodium lauryl sulfate (SLS). This anionic surfactant
may interact with cationic charges of gelatin at gastric pH (Pillay and Fassihi, 1999).
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These interactions may retard the disintegration of the capsule shell and thus
dissolution of the drug.

Larsen et al., (2002 and 2000) demonstrated that partitioning of testosterone from the
vegetable oils into a pH 6 buffer was correlated with in vitro release rates. Viscosities
of oils have not influenced the release of the drug. However, the viscosities studied
were very close to each other.

In the lipid based formulations, the effect of the properties oflipids on dissolution rate
and extent of the drugs has been hardly studied. Therefore, in this study, formulations
of nifedipine, developed with different classes of lipids and a surfactant combination,
were examined to investigate the effect of surfactant on the solubility and dissolution
of the drug. The effects ofphysicochemical properties of lipids on dissolution of
nifedipine were evaluated. Effect of particle size and partitioning behavior of
nifedipine on dissolution properties was also examined.

2. MATERIALS AND METHODS
2.1. Materials
Lipids that are used for this study listed in Table I were selected based on their class
and GRAS (Generally Recognized as Safe) status. The selected lipids included
glycerides (glyceryl tri- caprylate/caprate, glyceryl mono-caprylate/caprate and
glyceryl mono-oleate), polyglycerol (diglyceryl mono-oleate and triglyceryl monooleate) and propylene glycol esters (propylene glycol mono-caprylate, -laurate and -
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oleate). By selecting these lipids, the effects of hydrophilic (glyceryl, polyglycerol and

(

propylene glycol) and hydrophobic (fatty acid chain) groups oflipids on the
dissolution can be determined. The fatty acid distributions of lipids are also given in
the same table. The measured/calculated properties of the lipids (HLB, density, MW,
polarity and viscosity) were summarized in Table IL The details of these
measurements/calculations are already given in the Manuscript II. Because there is no
purification involved in the formulations with lipids, they were used as obtained.

The model drug chosen for this study was nifedipine, a calcium antagonist that is used
to treat angina and hypertension. It is 3, 5-pyridinedicarboxylic acid, 1, - dihydro-2, 6dimethyl-4-(2-nitrophenyl)-, dimethyl ester. It has a molecular weight of 346.34.
I

.

Nifedipine is practically insoluble in water (9.5 µg/mL at 25°C) and less soluble in
ethanol. It is also light sensitive and converts to a nitrosophenylpyridine derivative
when it is exposed to daylight and UV light. Therefore, all nifedipine related
experiments were carried out under yellow light.

Cremophor EL (BASF Corp., Mount Olive, NJ), polyoxyl 35 castor oil, was used as
the surfactant to improve the water miscibility of lipids. Cremophor EL
(Polyoxyethyleneglycerol triricinoleate 35) is a liquid non-ionic surfactant with a
critical micelle concentration (CMC) of0.0015 % w/v (Figurel). It is produced by the
chemical reaction of ethylene oxide with castor oil. The major components of
Cremophor EL are tri-glycerides which contain about 87% ofricinoleic acid. The
surfactant is presently used as a vehicle in the pharmaceutical preparations to increase
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the solubility of lipophilic drugs, including cyclosporine A and paclitaxel (Sparreboom
et al., 1996 and Meyer et al., 2001).

2.2. Methods

2.2.1. Solubility Determination
The mixtures of Cremophor EL and lipid vehicles shown in Table I were prepared at
varying lipid/surfactant ratios of 10/0, 9/1, 8/2, 7/3, 6/4, 515 w/w, which corresponds
to 0, 10, 20, 30, 40 and 50% (w/w) Cremophor EL concentration, respectively. Visual
observation of these mixtures was recorded. All lipid-surfactant combinations
produced clear solutions except Miglyol 810, which formed cloudy mixtures at all
ratios.

The solubility of nifedipine was determined in each lipid-surfactant combination and
in Simulated Gastric Fluid (SGF) by adding an excess amount of the drug into 10 g of
solvent and equilibrating the mixture for 72 hr. at 25° ± 0.1°C for lipid/surfactant
mixtures and 37° ± 0.1°C for SGF. The mixture was centrifuged for 10 minutes and
filtered through a 0.45µm filter. The amount of nifedipine dissolved was determined
by an HPLC method.

A Hewlett Packard 1050 HPLC system with a UV detector (A. =236 nm) was used for

nifedipine determination. The stationary phase consisted of a micro Bondapak, C 18
reverse phase column (3.9 x 300 mm, Waters Corp., Milford, MA). The mobile phase
used was acetonitrile: methanol: water (2: 3: 3) combinations. The samples were
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diluted with methanol before the runs. The flow rate used was I .0 mL/min with 30
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minutes of total run time per injection. The data acquisition was made using the
software Turbochrome 6.1.1.0.0 (Perkin Elmer Corp, Wellesley, MA). All studies
were performed in triplicate.

2.2.2. Interfacial Tension
A Kruss K 12 Tensiometer (Kruss USA, Charlotte, NC) was used to determine the
interfacial tension between the selected lipid and simulated gastric fluid (SGF), USP.
The ring method was selected for the measurements. Both the lipids and SGF were
used at 37°C.

All the lipids used except Capmul MCM in Table I were less dense than SGF, USP.
First, surface tension of the lipids was measured in a vessel then the vessel was
emptied and cleaned. The heavy phase (SGF) was placed in the vessel, and then the
ring was dipped in the liquid. The lipids were slowly added into the vessel by making
sure no mixing occurred at the interface. Interfacial tension was determined by pulling
the ring away from interface, the "pull" method.

2.2.3

Formulation Development

Among all surfactant/lipid mixtures, the ones containing 0, 10, and 40% w/w
Cremophor EL have been selected for formulation development of nifedipine. The
drug (10 mg) was added to the lipid/surfactant combination (4.5 g) and mixed in a
shaker at the room temperature until it was completely dissolved. The final solutions

l
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that were examined under a polarizing microscope were crystal-free. The solutions
obtained were filled into "000" size hard-gelatin capsules and sealed with a bending
solution that contained 20% w/v gelatin, 0.8% w/v polysorbate80 and water to make
final volume 100 mL. The capsules were kept at the room temperature and assayed for
nifedipine. The assay conducted using the HPLC method showed that the formulations
were stable at the room temperature for two months containing 100 ± 2% nifedipine.

2.2.4. Dissolution Test
The USP II apparatus with paddle at a speed of 50 rpm and a temperature of37°±
0.1°C was used to obtain dissolution profiles for the nifedipine lipid capsules.
Simulated gastric fluid (pH =1.2, 900 mL) was used as the dissolution medium. Since
the solubility of nifedipine is low, Cremophor EL was added to dissolution medium to
increase the solubility of drug. Cremophor EL concentration of 3% (w/v) was selected
to increase the solubility of nifedipine (Table III) and can differentiate dissolution of
nifedipine from different formulations.

Four capsules that have total of 10-mg drug were placed in capsule cages and dipped
into the dissolution medium Samples (3 mL) were withdrawn using a syringe that was
attached to a cannula with a 10 µfilter at 3, 5, 8, 10, 15, 20, 40 and 60 minutes. The
withdrawn sample was replaced with 3 mL fresh dissolution medium. The amount of
dissolved nifedipine was determined by the HPLC method as explained in Section
2.2.1.

(
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The percentage of nifedipine dissolved at 60 minutes was taken as the dissolution
extent of the formulation. The dissolution rates were calculated using the Kitalllwa
equation (Pillay and Fassihi, 1999):
Ct = Co. ekt or

ln ( C1) = Co - kt

where

Equation 1

Ct is the remaining concentration of nifedipine at time t, Co is the initial

concentration and k is the dissolution rate. Therefore, the slope of the plot ln (C 1) vs.
time in the linear region was taken as the dissolution rate.

2.2.5. Partition Coefficient
Partitioning of nifedipine from a respective formulation to the dissolution medium was
obtained by mixing an equal amount of formulation and SGF + 3% Cremophor EL for
1 hr at 25°C. The aqueous and oily phases of the mixture were separated by
centrifuging the mixtures for 10 min at 2000 rpm. The oily phase separated was
assayed for nifedipine.

2.2.6. Particle Size Measurement
Light scattering was used for the particle size measurements of the formulations that
were obtained by dissolving them in SGF. The dissolution conditions were used for
the particle size determination. Four capsules that have total of 10-mg drug were
placed in capsule cages and dipped into the dissolution medium (900 mL), containing
3% w/v Cremophor EL. 5 mL sample was withdrawn at I 0, 20, 40 and 60 minutes and
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the particle sizes were measured using a Dynamic Light Scattering (Brookhaven
Instrument Corp. Holtsville, NY). The measurement duration was one minute at the
wavelength 488 nm and the detector angle 90°. Polydispersity index monitored was
within 0.2% range.

2.2. 7. Statistical Analyses

The effect of Cremophor EL concentration on the solubility of nifedipine in lipids has
been analyzed using linear regression. The model used is expressed as:
Equation 2

Where SN is the solubility of nifedipine (mg/g) in the mixture, SL is the intercept and
(

represents the solubility of nifedipine (mg/g) in the lipid, Cs is the surfactant
concentration(% w/w) and a is the slope and represents solubility rate. Correlation
coefficient (Rad/) has been obtained. Goodness of fit test has been performed using
Shapiro-Wilk hypothesis. For the Shapiro-Wilk test, a test statistic, W, is calculated
and is used to test following hypotheses:

Ho: The distribution is normal distribution
Ha: The distribution is different from normal distribution
If the probability of Wis higher than 0.05, the conclusion is fail to reject H0 .

Similarly, the effect of physicochemical properties of lipids, partitioning of nifedipine
and particle size of nifedipine lipid-based formulations on dissolution has been
analyzed using a simple linear regression analysis and correlation coefficient (Rad/)

(

has been obtained. Goodness of fit test has been performed.
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JMP Statistical Software version 4.0.4 (SAS Institute Inc, Cary, NC) has been used for
all analyses.

3.
3.1.

RES ULTS AND DISCUSSIONS
The Role of Cremophor EL and on the Solubility and Dissolution of
Nifedipine in Lipids

The mixtures of lipid and Cremophor EL were clear except the
Migl yo 181 O/Cremophor EL mixtures. The solubility of nifedipine in these mixtures is
given in Table IV. As it can be seen from the results, addition 10-50% (w/w) of
Cremophor EL increases the solubility of the drug around 10 to 600 times. Surfactant
related increase in solubility(%) resuhs in Table IV showed that the highest percent
increase was observed with Caprol 2GO (662%), which has the lowest nifedipine
solubility and the lowest percent increase was observed with Capmul Pg-8 (12%),
which provided the highest solubility for nifedipine. These results indicated that the
effect of surfactant on the solubility ofnifedipine is more dominant, if the solubility of
the drug in a lipid is low. The increase in solubility is proportional to the amount
surfactant added, Figure 2 and the surfactant concentration and solubility obeyed:
Equation 3

All the statistical parameters, the slope (a), intercept SL (solubility of nifedipine in
lipid) and correlation coefficient (Rad/) values obtained using Equation2 are tabulated

(

in Table V. Goodness of fit test showed that normal distribution is followed for all
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lipids (p >0.05) and the model is adequate. Data in Table V also showed that slopes
are the same for the same homolog series of lipids. For example, polyglycerols like
Capmu!GMO (Glyceryl mono-oleate), Caprol2GO (Di-glyceryl mono-oleate) and
Caprol3GO (Tri-glyceryl mono-oleate) have a slope of 0.41 and propylene glycol
esters namely CapmulPG-8 (Propylene glycol mono-caprylate), CapmulPG-12
(Propylene glycol mono-laurate) and CapmulPG-18 (Propylene glycol mono-oleate)
have the slope around 0.38. The increasing surfactant concentration affected
polyglycerol esters more than propylene glycol esters because the effect of surfactant
on the solubility of nifedipine is more dominant with lipids dissolves the drug at lower
extent.

Dissolution profiles of the formulations that contained Cremophor EL showed that
addition of 10% (w/w) surfactant in the formulation increased the rate of dissolution,
Figure 3. An additional increase of surfactant in the formulation did not show further
difference, regardless of the type of lipid. Figure 3 is an example to the dissolution
performance of 10 -40% Cremophor EL containing nifedipine lipid formulation.
Overall findings indicated that the presence of 10% Cremophor EL has hidden the
variations involved in the dissolution caused by the lipids because micelle-facilitated
dissolution takes over when there is sufficient surfactant presents in the formulation.

3.2.

Effect of Lipids on Nifedipine Dissolution

The dissolution profiles of the formulations containing 10 mg nifedipine, 4.5 g of lipid
and no surfactant are given in Figure 4. The highest and complete dissolution of
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nifedipine was obtained with Capmul MCM. Although the highest solubility of
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nifedipine was obtained in Capmul PG-8, it showed the lowest dissolution rate and
extent for nifedipine.

When the dissolution performance of the drug in a lipid series containing increasing
fatty acid chain length compared, it was found that increasing chain length increased
the dissolution rate and extent, Figure 5. The decrease in solubility of nifedipine with
increasing fatty acid chain length may be the reason of the increment observed in the
dissolution rate and extent. However, Table IV and Figure 4 demonstrated that
solubility of nifedipine in Capmul MCM (glyceryl mono-caprylate/caprate) is similar
to Capmul PG-8 solubility (Propylene glycol mono-caprylate) and yet Capmul MCM
I
'

provided much higher dissolution extent and rate. This occurrence suggests the role of
additional factors that may influence the dissolution of the drug from the lipids. These
factors may be partitioning behavior of the drug, viscosity, polarity and density of the
lipid.

The dissolution rate and the extent of nifedipine given in Table VI compared with the
solubility of the drug in the lipids, physicochemical properties of lipids (HLB, density,
viscosity and interfacial tension) given in Table II showed that the effect of each factor
is significant on dissolution rate and extent (p<0.005 with one way ANOV A). When
the drug has high lipid solubility, lipid tends to keep the drug itself and does not Jet it
release into aqueous medium. However, if the lipid is hydrophilic which can be
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defined by HLB, interfacial tension, polarity, dissolution extent of the drug can be
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improved highly like it happens in Capmul MCM (96% dissolved in an hour).

Density and viscosity were the other important properties of lipids affected dissolution
rate and the extent of nifedipine, Tables II and VI. Relatively low density of the lipid
resulted in floating of the formulation on surface of the dissolution fluid and slowed
the release of the drug. Also as the viscosity of the lipid increased, the mixing time of
the formulation was extended hence the dissolution rate and the extent was lowered.

The dissolution performance of nifedipine in the lipids was further evaluated using
two parameters; dissolntion extent and rate of nifedipine from each lipid given in

(

Table VI. These values used to investigate the contribution of each factor to
dissolution parameters. The statistical evaluations were carried out with the linear
regression analyses. Among individual tests, only meaningful relationship was found
between dissolution extent and partition coefficient of the drug (Radj2 = 0.991).

Partition coefficient of nifedipine from formulations to the dissolution medium has
been given in Figure 6. The drug partitioned in propylene glycol (PG) esters in the
highest order. The increasing fatty acid chain from C8 to C18 decreased the partition
coefficient from 9.6 to 7.8. Partitioning of drug from lipid to aqueous phase decreased
as the solubility of drug increased in the lipid. Dissolution extent was significantly
affected by partitioning, Figure 7. As the partition coefficient of drug from increased,

130

dissolution rate decreased producing a correlation coefficient of Rad/= 0.991

(

between dissolution extent and partition coefficient of nifedipine.

Particle size of the lipid-formulation in the GI fluid can also be an important factor
that affects the dissolution of nifedipine. The smallest particle size was obtained from
Capmul MCM which provided as small particle as the Miglyol810/CremophorEL
mixture did, Table VII. During one hour mixing, the particle size of formulation did
not change by time. The linear regression analyses showed that the particle size of
each lipid at 60 minutes was correlated well with the dissolution extent at 60 minutes
(R 2adj =0.9758 and p=0.1733 for goodness of fit) and partition coefficient of
nifedipine (R 2 adj =0.9835 and p= 0.3146 for goodness of fit). As the particle size
increased, dissolution extent decreased and partition coefficient (Po/w) increased,

(

Figure 8. These results also confirm the findings by Shah et al., (1994). As the particle
size decreases, the surface area increases so that dissolution enhances.

4.

CONCLUSION

Incorporation of Cremophor EL, a nonionic surfactant, into lipid-based nifedipine
formulation enhanced the solubility and dissolution of nifedipine. The solubility of
nifedipine showed a linear correlation with surfactant concentration. While solubility
rate was dependent on the type of lipid used, the dissolution of nifedipine in presence
of surfactant was the same regardless of lipid used.

(
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Dissolution of nifedipine from lipids showed that as the fatty acid chain length
increases, the dissolution rate increases due to lower solubility of nifedipine in the
lipids that have higher chain length. The effect of lipids on dissolution rate and extent
of nifedipine investigated showed that even though physicochernical properties of
lipids (HLB, interfacial tension, viscosity, density) and solubility of nifedipine in
lipids play role, only partitioning of the drug from lipid to aqueous medium and
particle size of the formulation in dissolution medium were provided a good
correlation with dissolution extent of nifedipine.
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Table I. Lipids used in this study
Classification and chemical

Chemical Name

Trade Names

distribution)

structure
Triglycerides

Composition (% fatty acid

Caprylic (Cs) I

Miglyol 810

Cs: 71

Capmul MCM

Cs: 81 C10: 18 C6: 1

Glyceryl mono-oleate

Capmul GMO

C1 s: 1: 80 C1s:2: 10 C1 s: 4 C1 6: 4 C1 4: 2

Diglyceryl mono-oleate

Caprol 2GO

C1 s: 1: 90 C1 s:2: 3 C1 s : 3 C1 6 : I

Triglyceryl mono-oleate

Capmul 3GO

C1 s: 1: 90 C1 s:2: 3 C1 s : 3 C1 6 : I

Propylene glycol mono-caprylate

Capmul PG-8

Cs: 99

Propylene glycol mono-laureate

Capmul PG-12

C1 2: 98 C1 4: 2

Propylene glycol mono-oleate

Capmul PG-18

C1 s: 1: 93 C1 s:2: 3 C1 s : 3 C1 6 : 1

C10: 29

Capric (C1 0) triglyceride
Glyceryl mono-/ di-esters

Mono-and di-glyceride of caprylic
/capric acid

(.,..)

0\

Polyglycerol esters
Propylene glycol esters

C 10: 1

* C6: Caproic, Cs: Caprylic, C10: Capric, C1 2: Laurie, C14: Myristic, C14:l: Myristoleic, C 16 : Palmitic, C 16: l: Palmitoleic, C 1s : Stearic,
C 1s:1 : Oleic, C 1s 2 : Linoleic and C1 s:3: Linolenic acid

~

Table II. Calculated and measured properties of lipids used
Lipid

HLB

Density (g/cm 3)

MW

Viscosity (cP)

Dielectric constant

Interfacial tension (mN/m) at 37°C

Miglyol 810

l.5

0.9437

495

15

2.0958

12.00

Capmul MCM

6.5

l.0022

275

65

2.1048

Not measurable

Capmul GMO

4

0.9451

490

325

2.1574

3.16

Caprol 2GO

5

0.9814

421

760

2.1697

2.70

Caprol 3GO

6

0.9776

494

1090

2.1691

2.43

Capmul PG-8

5

0.9387

202

1

2.0630

3.23

Capmul PG-12

4

0.9183

258

15

2.0863

3.12

Capmul PG-18

3.5

0.9096

340

25

2.1293

3.15

V.l

-.J

(

Table III. Nifedipine solubility in Simulated Gastric Fluid at 37°C containing
Cremophor EL
Cremophor EL(% w/v))

Solubility (mg/mL)

0

0.0054

0.5

0.0548

1

0.1032

2

0.2104

3

0.3148

5

0.5739

7

0.7885

10

1.1641

12

1.4551

15

1.7048
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Table IV. Solubility of nifedipine in lipid/Chremophor EL mixtures
Lipid vehicle

Miglyol 810
Glyceryl tri

Cremophor EL

Nifedipine solubility

% increase in

concentration %
0

mg/g mean± SEMn=3
3.359 ± 0.029

solubility
0

10

4.863 ± 0.043

43

20

10.183 ± 0.087

197

30

17.940 ± 0.123

418

40

23.702 ± 0.091

577

50

18.276 ± 0.083

415

0

10.273 ± 0.091

0

10

14.368 ± 0.037

39

20

16.738 ± 0.047

61

30

23.873 ± 0.089

129

40

23.720 ± 0.023

126

50

26.478 ± 0.124

151

0
10

3.115±0.111
8.878 ± 0.094

0
182

20

11.758 ± 0.087

269

30

16.456 ± 0.108

411

40

18.591±0.056

472

50

24.825 ± 0.083

657

0

3.026 ± 0.037

0

10

7.055 ± 0.148

131

20

10.221 ± 0.097

231

30

14.657 ± 0.084

370

40

19.548 ± 0.174

521

50

24.143 ± 0.267

662

caprylate (Cs)

Capmul MCM
Glyceryl monocaprylate (Cs)

CapmulGMO
Glycerylmonooleate (C1s:1)

Caprol 2GO
2-glyceryl monooleate (C1s:1)
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Table IV: Solubility of nifedipine in lipid/Chremophor EL mixtures (continued)
CremophorEL

Nifedipine solubility

% increase in

concentration %
0

m_glg_ mean± SEM n=3
3.193 ± 0.099

solubility
0

10

6.217 ± 0.122

93

20

10.679 ± 0.165

230

30

12.353 ± 0.465

279

40

19.385 ± 0.345

490

50

24.304 ± 0.655

635

0

16.983 ± 0.555

0

10

19.256 ± 0.426

12

20

23.304 ± 0.457

34

30

27.750 ± 0.589

58

40

31.226± 0.891

76

50

40.032 ± 0.924

123

0

8.118 ± 0.243

0

10

10.717 ± 0.094

30

20

13.287 ± 0.243

60

30

18.792 ± 0.145

122

40

23.359 ± 0.456

173

50

18.055 ± 0.754

110

0

5.068 ± 0.035

0

Capmul PG-18

10

8.728 ± 0.216

70

Propylene glycol

20

10.990 ± 0.556

112

30

14.683 ± 0.423

178

40

21.050 ± 0.589

293

50

30.176± 0.812

455

0

58.23 ± 1.632

-

Lipid vehicle

Caprol3GO
3-glyceryl monooleate (C1 s: 1)

Capmul PG-8
Propylene glycol
mono-caprylate
(Cs)

Capmul PG-12
Propylene glycol
mono-laurate
.1C.l2l

mono-oleate
(C1s:1)
Cremophor EL
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Table V. List of parameters for Equation 2 to investigate the effect of surfactant concentration on the solubility of
nifedipine (SN) in lipids

--

Lipid

R adj

a (slope)

SL

p for goodness of fit

Miglyol810 (Glyceryl tri-caprylate)

0.782

0.40

3.12

0.9637

CapmulMCM (Glyceryl mono-caprylate)

0.915

0.36

10.51

0.3470

CapmulGMO(Glyceryl mono-oleate)

0.981

0.41

3.76

0.7663

Caprol2GO (Di-glyceryl mono-oleate)

0.994

0.42

2.57

0.1856

Caprol3GO (Tri-glyceryl mono-oleate)

0.967

0.42

2.21

0.1153

Capmu!PG-8 (Propylene glycol mono-caprylate)

0.987

0.37

16.30

0.2789

CapmulPG-12 (Propylene glycol mono-laurate)

0.964

0.38

7.146

0.6537

CapmulPG-18 (Propylene glycol mono-oleate)

0.955

0.38

4.52

0.8131

.j:::..

r
Table VI. Dissolution parameters of nifedipine in various lipids (n =3)
Lipid

Miglyol810

Dissolution rate (k)*

Dissolution extent ( % )

(Mean± SD)

(Mean± SD)

0.012 ± 0.000

50.19 ± 1.44

0.254 ± 0.009

96.05 ± 0.28

0.021±0.002

79.64 ± 1.44

0.074 ± 0.002

76.58 ± 0.99

0.081 ± 0.009

73.12 ± 0.43

0.006 ± 0.000

30.27 ± 3.54

0.008 ± 0.002

31.85 ± 2.93

0.015 ± 0.001

45.73 ± 2.50

(Glyceryl tri-caprylate)
Capmul MCM
(Glyceryl mono-caprylate)
Capmul GMO
(Glyceryl mono-oleate)
Caprol2GO
(Di-glyceryl mono-oleate)
Caprol3GO
(Tri-glyceryl mono-oleate)
Capmul PG-8 (Propylene
glycol mono-caprylate)
Capmul PG-12 (Propylene
glycol mono-laurate)
Capmul PG-18 (Propylene
glycol mono-oleate)
*k: calculated using Equation 1
#%dissolved nifedipine at 60 minutes
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Table VII. Results of particle size of nifedipine in each lipid at 37°C
Particle size (nm, mean ± SD, n=3)
Lipid

10 min

20 min

40 min

60min

Miglyol810

NIA*

NIA *

NIA*

NIA*

CapmulMCM

10 ± 0.5

12 ± 1.1

12 ± 1.5

11±0.5

Capmul GMO

322 ± 11

328 ± 8

337 ± 12

333 ± 28

Caprol 2GO

473 ± 36

434 ± 28

433 ± 28

454 ± 45

Caprol 3GO

459 ± 24

419 ± 28

418 ± 32

417 ± 28

Capmul PG-8

800 ± 4.7

786 ± 24

765 ± 27

777 ± 32

Capmul PG-12

732 ± 26

726 ±9

728 ± 26

724 ± 5

Capmul PG-18

727 ± 23

723 ± 21

730 ± 26

707 ± 8

Miglyol8101

11±1.0

11±2.1

10 ± 1. 3

10 ± 1.2

Cremophor EL
* NI A: not applicable. The mixture is too coarse to measure
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Figure 1. Critical micelle concentration (CMC) of Cremophor EL (n=3)
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Figure 2: The effect of concentration of CremoPhor £z, the solubility of nifedipine
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Figure 3: Effect of surfactant concentration on dissolution of nifedipine from Capmul
PG-8
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Figure 4. Effect of lipid on dissolution of nifedipine
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Figure 5. Effect of fatty acid chain length on dissolution of nifedipine from propylene
glycol esters
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Figure 6. Partition coefficient (oil/water) of
nifedipine with different vehicles
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Figure 7. Effect of partitioning of lipids from nifedipine
formulation to dissolution medium on dissolution extent
of nifedipine
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Figure 8: Effect of partitioning and dissolution extent on
particle size of the nifedipine formulation in lipids
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1. INTRODUCTION

(

The use of lipid formulations generated considerable interest in the last two decades
because the modem drugs produced are highly lipophilic as the result of High
Throughput Screening (HTS). The lipids may improve the bioavailability of drugs
through several mechanisms such as by enhancing their solubility/ dissolution (Pozzi
et al., 1991; Sheen et al., 1991; Charman et al., 1992; Shah et al., 1994; Matuszewska
et al., 1996; August et al., 1997), by homogenously dispersing the drug into the gastric
fluid and providing and uniform absorption rate (Yamahira et al, 1979a, b, 1980) and
by increasing lymphatic absorption (Cheema et al., 1987; Charman and Stella, 1992).

Despite numerous studies with lipid-based system to increase the bioavailability of

(

poorly soluble drugs, only a relatively few commercial formulations of lipid-based
systems are available on the market. These are cyclosporine (Sandimmune™ and
Neoral™, Novartis), saquinavir (Fortovase™, Roche), ritonavir (Norvir™, Abbott) and
fat-soluble vitamins. Among the reasons for limitation of their use may be not to have
sufficient knowledge of in vitro and in vivo performance of these type of formulations.
Lipolysis that takes place in upper intestine is a physiological event that makes it more
difficult to predict in vivo performance of lipid-based formulations.

Understanding of the lipid digestion process is important in design of the lipid-based
formulations. The digestion process involves three basic steps: (I) dispersion of lipid
solution into the gastric media and emulsification of the solution by the gastric
movements, (II) enzymatic hydrolysis of di- and tri-glycerides into mono-glyceride
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and fatty acids, (III) formation of the mixed micelles with hydrolysis products and bile

(

salts and ultimately absorption of lipids through the intestinal wall (Carey et al., 1983).
Only tri-glycerides are digested physiologically. The pharmaceutical grade diglycerides are rare. When a mono-glyceride is used in a formulation, it is assumed that
it skips the enzymatic hydrolysis step. Therefore, dissolution studies may be predictive
of the bioavailability of such systems.

Micelle formation of lipolysis products with bile salts is the crucial step that enhances
the solubility and absorption of poorly soluble drugs. The total solubility of
compounds such as steroids, griseofulvin, cyclosporine A, danazol, pentazocaine,
triamcinolene and diazap""m was found to be pr0portional to taurocho 1ate
concentration, a major bile salt present in the small intestine. A linear relationship was

(

shown between solubilization and partition coefficient of steroids, cyclosporine A, and
griseofulvin (Mithani et al., 1996).

A detailed discussion of the lipid digestion process and its impact on drug absorption
from the gastro-intestinal tract can be found in several reviews (Eldem and Speiser,
1989; Embleton and Pouton, 1997; 1997; MacGregor et al., 1997; Dumanli et al,
2002). However, there are not many published studies investigated the correlation

between in vitro lipolysis and in vivo results. MacGregor et al. (1997) briefly
mentioned the lipolysis of progesterone that was formulated with two SEDDS and
compared with plasma profiles an oily suspension. The AUCs of the lipid formulations
were 8-10 times more the suspension. The SEDDS formulations formed small
(
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droplets, uniformly dispersed in the GI system and undergone lipolysis were

(
I

demonstrated good in vitro in vivo coITelation. Reymond et al. (1988a and b) described
an in vitro study where lipid emulsion was formulated with controlled particle size and
followed the bioavailability of drug from such emulsions in the male rats via urine
excretion. They have concluded that in vitro lipolysis could not simulate in vivo
performance of the formulations.

In order to coITectly predict in vivo performance of lipid formulations, more than one
evaluation technique such as dissolution, particle size determination and solubility of
the drug in the lipids and GI fluids may be needed.

In this study, the bioavailability of nifedipine from different lipid formulations was
determined in the beagle dogs. The types of lipids were determined from our previous
study in which in vitro dissolution performance of a nifedipine formulation in
CapmulPG-8 (propylene glycol mono-caprylate), CapmulPG-12 (propylene glycol
mono-laurate), CapmulPG-18 (propylene glycol mono-oleate), CapmulMCM
(glyceryl mono-caprylate/caprate), Miglyol810 (glyceryl tri-caprylate), Caprol2GO
(diglyceryl mono- oleate), Caprol3GO (tri-glyceryl mono-oleate) and CapmulGMO
(glyceryl mono-oleate) was investigated (Manuscript III). Among these lipids, we
have selected CapmulMCM, which provided the highest dissolution rate, Capmul
PG8, which provided the lowest dissolution rate and Miglyol810, which provided
relatively moderate dissolution rate, for the further in vivo studies. The latest lipid is a
tri-glyceride which undergoes to lipolysis, while Capmu!MCM and Capmu!PG-8 are

(
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mono-glycerides and therefore are not subjected to the lipolysis process. To seek an in

(

vitro and in vivo correlation, the solubility, partitioning and particle size of nifedipine
in the given lipids were also determined.

2. MATERIALS AND METHODS
2. 1. Materials
Nifedipine and butamben (an internal standard for HPLC analyses of nifedipine in
plasma) were purchased from Sigma, Louis, MO, Capmul MCM (Mono-glyceryl
caprylate/caprate) and Capmul PG-8 (Propylene glycol caprylate) were provided by
Abitec, Columbus, OH. Miglyol810 (tri-glyceryl caprylate/caprate) and Cremophor
EL (PEG-35 Castor oil,) were gifts from Sasol, NJ and BASF, Germany, respectively.

(

All the lipids have GRAS (Generally Recognized as Safe) status. Methanol,
acetonitrile, chloroform, acetone, phosphoric acid were purchased from Fisher
Scientific., Springfield, NJ. All the chemicals were used as received.

2.2. Methods
2.2.1. Preparation of Formulations
Nifedipine (100 mg) was dissolved in each lipid vehicle (4.5 g) at 25°C in a shaker.
All formulations were in clear liquid form and there were no changes observed when
they were kept at 4°C for a month. The components of the formulations were given in
Table 1. The fo1mulations A-C contained 100 mg nifedipine and 45 g lipid in each
batch. Fo1mulation D contained 100 mg nifedipine, 4.5 g Cremophor EL and 40.5 g
Miglyol 810. Each formulation (1.1250g containing 2.5 mg nifedipine) was filled into
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a "000 size" hard-gel capsule sealed with a bending solution to prevent the leakage.
The bending solution contained 20% (w/v) capsule shells, 0.8 % (w/v) Tween80 and
distilled water and was kept at 40°C during sealing.

2.2.2. Nifedipine Assay in the Formulations
Nifedipine content of the each formulation was determined by an HPLC method
described in Section 2.2.3.l. The determination was made by weighing around 0.14 g
of the formulation that contained 0.078 mg nifedipine, diluting with methanol and
analyzing at 238 nm.

2.2.3. In vitro Tests
2.2.3.1. Solubility Determination
The solubility of nifedipine was determined in each lipid vehicle by adding an excess
amount of the drug into 10 g of the vehicle mixture and equilibrating the mixture at
25 ° ± 0.1 °C for 72 hr. The mixture was centrifuged for 10 minutes and filtered
through a 0.45µm filter. The amount of nifedipine dissolved was determined by the
HPLC method.

A Hewlett Packard 1050 HPLC system with a UV detector (A. =236 nm) was used.
The stationary phase consisted of a micro Bondapak, C 18 reverse phase column (3.9 x
300 mm, Waters Corp., Milford, MA). The mobile phase used was acetonitrile:
methanol: water (2: 3: 3) mixture. The samples were diluted with methanol before the
run and the flow rate was 1.0 mL/min with 30 minutes of total run time per injection.
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The data acquisition was made using the software Turbochrome 6.1.1.0.0 (Perkin
Elmer Corp, Wellesley, MA). All studies were performed in triplicates.

2.2.3.2. Dissolution Test
The USP II apparatus with paddle at 50 rpm and 37°± 0.1°C was used to obtain
dissolution profiles for the nifedipine lipid capsules. Simulated gastric fluid (SGF)
(pHl.2, 900 rnL) was used as the dissolution medium. Since the solubility of
nifedipine is low in SGF, Cremophor EL, a nonionic surfactant, was added to the
dissolution medium to increase the solubility of drug. Cremophor EL concentration of
3% (w/v) was high enough to improve and maintain the solubility of nifedipine and to
differentiate dissolution of nifedipine formulations used. Four capsules containing
total 10-mg of drug were placed in capsule cages then dipped into dissolution vessel.
Samples (3 rnL) were withdrawn using a syringe attached to a cannula that has a 10 µ
filter at the tip at 3, 5, 8, 10, 15, 20, 40 and 60 minutes. The sample withdrawn was
replaced with 3 rnL fresh dissolution medium. The amount of dissolved nifedipine was
determined by the HPLC method as explained in Section 2.2.3.1.

The amount of dissolved nifedipine (%)at 60 minutes was taken as the dissolution
extent of the formulation.

2.2.3.4. Partition Coefficient
The partition coefficient of the drug between the formulation and the Simulated
Gastric Fluid (SGF) USP, was obtained by mixing equal amount of formulation and
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SGF + 3% Cremophor EL for l hr at 25°C. The phases were separated by
centrifuging the mixtures for 10 min at 2000 rpm. The oily phase was assayed for the
amount of the drug analyzed by the HPLC method given in Section 2.2.3.l.

2.2.3. 5. Particle Size Measurements
The dissolution apparatus described in Section 2.2.3.2 was used for the particle size
measurements. Four capsules that contained a total of 10-mg drug were placed in the
capsule cages and dipped into the dissolution medium (900 mL SGF contained 3%
w/v Cremophor EL). Sample (5 mL) was withdrawn at 10, 20, 40 and 60 minutes and
the particle sizes were measured using a Dynamic Light Scattering (Brookhaven
Instrument Corp. Holtsville, NY). The measurement duration was one minute at 488
nm and at 90° of detector angle. Polydispersity index monitored was within 0.2%
range.

2.2.4

In vivo Absorption Study Design

2.2.4.1. Test Animals
The bioavailability of nifedipine lipid formulations was tested on six fasted beagle
dogs using a single dose crossover design. The washout period between the
experiments was one week. The dogs were supplied by The Marshall Farms, North
Rose, NY. They were approximately 7-10 kg in weight and 13-16 months old and
were acclimatized for at least three weeks prior to study.

I
\
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The study group consisted of 3 males and 3 females. Each dog had an ear tattoo and
was housed individually in a stainless steel cage that has an identification card
showing compound number, study number, dose level and dog number and sex. Room
temperature and humidity was maintained at approximately 72° ± 4°F and 50% ±19%,
respectively. The animal room was on an approximate 12-hour light/dark cycle. Dogs
were exercised outside the cage at least three times a week for at least 15 minutes.

2.2.4.2. Dosage forms, frequency and method of dosing
The dogs were fasted overnight prior to experiment. Each dog received four 2.5 mg
nifedipine capsules (Details of the protocol were given in Table II). Each dog received
approximately 500g Teklad Glohl Certified 21 % protein Dog Diet 2021C f hours
after dosing. Water, purified via reverse osmosis (RO), was available ad libitum by
means of an automatic watering system. The RO water supply for each active animal
room was monitored for bacterial contamination at least once a month by the
Department of Laboratory Animal resources. In addition, chemical analysis of water
was performed at approximately quarterly intervals by the Environmental Monitoring
and Support Laboratory. No contaminants expected to interfere with the study were
known to be present in the feed or water.

2.2.4.3. Blood sampling
Blood samples (lmL) were collected via jugular vein from each dog at 0, 1, 2, 3, 6, 10
and 24 hours and placed into glass tubes containing EDTA used as an anticoagulant.
The tubes were kept at 4°C to prevent decomposition. The plasma was separated from
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the whole blood with centrifugation at 4°C, transferred to screw- cap vials and was
kept frozen in a -70°C freezer until assay time.

2.2.5. Assay of nifedipine in plasma
Nifedipine in all samples was assayed using a modified version of the HPLC method
described by Mehta et al. (2002). In this method, a vortex mixer (Scientific Industries
Inc., Bohemia, NY) was used to equilibrate the frozen samples at room temperature.
Methanol (100 µl) containing 2 µg/mL butamben (as the internal standard) and
acetonitrile (2 mL) were added to 0.5 mL plasma and vortex mixed for 30 minutes.
After centrifugation at 4000 rpm for 15 minutes with a Hermie Centrifuge
(ModelZ382K, Denville Scientific, Metuchen, NJ), 2 mL of supernatant was
transferred into a test tube containing 1 mL of distilled water. Acetone-chloroform
mixture (4.5 mL, 1:1 v/v) was added to this mixture and was shaken for 1 hour. This
solution was further centrifuged at 4000 rpm for 15 minutes to separate organic phase
from aqueous phase. The aqueous phase was discarded. The organic phase transferred
into an amber color test tube, and dried in a Turbovap LV ZW700 evaporator (Zymark
Corp., Hopkington, MA) at 45°C for an hour under nitrogen. The residue was
dissolved in 100 µI mobil phase, vortex-mixed for 30 seconds, transferred into
Eppendorf tubes and centrifuged at 14000 rpm for 10 min. The aliquot (25µ1) obtained
was injected to the HPLC system for nifedipine determination.

A Hewlett Packard 1050 HPLC system with a UV detector (A =238 nm) was used.
The stationary phase used was a reverse phase Zorbax RX-C18, 5-micron, 25cm x 4.6
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mm column (Agilent Tech., Palo Alto, CA). The column temperature was kept at
55°C. The mobile phase consisted of 0.01 M disodium hydrogen phosphate buffermethanol (45 :55, v/v) mixture. The pH of the buffer was adjusted to pH=6. l with 40%
phosphoric acid. Run time used was 20 minutes and the flow rate was 0.8 mUmin.
The data acquisition was made using the software Turbochrome 6.1.1.0.0 (Perkin
Elmer Corp, Wellesley, MA).

The calibration graph was obtained by adding nifedipine solution in methanol to drugfree plasma. Nifedipine plasma solutions were prepared at concentration of 0, 10, 20,
40, 80, 120, 160, 200 and 240 ng/mL and stored in a -70°C freezer for pending
analysis. The samples we 1 ~

processed

as describ2d above. The ratios c ~ the peak area

of nifedipine to that of butamben were used to construct a calibration graph,
Appendix , Figure16. CV for precision of the experiment was within 2%.

2.3.6. Pharmacokinetic analysis
Pharmacokinetic parameters were calculated from nifedipine plasma concentration.
Maximum plasma concentration (Cmax), time of occurrence of Cmax (Tmax) and
area under the curve (AUC 0_24 h) was calculated using WinNonlin software by
Pharsight Corporation (Mountain View, CA).

2.3.7

Statistical Analyses

Results for plasma concentrations were presented as mean ± SEM (standard error
mean). Statistical comparisons of pharmacokinetic parameters were performed using t-
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test for each pair. JMP Statistical Software version 4.0.4 (SAS Institute Inc, Cary, NC)
has been used for analysis.

3. RESULTS AND DISCUSSION
The assay demonstrated that nifedipine lipid formulations contained 99-102 % of the
original nifedipine loading. The plasma concentrations obtained after dosing each
animal with respective formulations are presented in Table III. One of the female
dogs (F4) vomited the Formulation A 10 minutes after the administration. Therefore,
the results obtained from this dog excluded from further calculations.

Table IV shows the mean pharmacokinetic parameters (Cm:-.x, T max, AUCo-24 h) of the
respective formulations and Figure 1, the plasma concentration profiles obtained
during 10 hours following administration. As seen in Table IV and Figure 1, Tmax
values obtained from formulation A, B, C and D were not significantly different from
each other (p>0.05) demonstrating that neither the lipids nor the surfactant added
influences the absorption time of nifedipine. On the other hand, Cmax and AUCo-24
values of formulations were significantly different from each other (p<0.05). The
highest plasma profile was obtained with nifedipine formulations containing
Miglyol810/Cremophor EL (9/1) and the lowest with the formulation containing
CapmulPG-8. The highest Cmax and AUC 0 _24 are the result of the micelle formation
ability of Cremophor EL in GI medium and thus improved solubility of nifedipine.
The bioavailability of nifedipine from formulation Dis followed by C>B>A. The
reason for higher bioavailability with Miglyol810 (glyceryl tri-caprylate) compared
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with CapmulMCM (glyceryl mono-caprylate/caprate) can be explained by Iipolysis.

r
'

Miglyol810 is a tri-glyceride and broken down to mono-glyce1ide and fatty acids
during lipolysis whereas CapmulMCM is a mono-glyceride and stays as it is during
the digestion process. Although both form micelles with bile salts, digestion of
Miglyol810 will generate higher amount of fatty acids. Therefore, the amount of
micelles produced in the presence of bile salts with Miglyol810 will be higher than the
micelles formed with CapmulMCM. Sek et al. (2002) also clearly demonstrated that
the effect of bile salt on Miglyol812 was more pronounced than on CapmulMCM by
an in vitro lipolysis experiment. A higher bile salt concentration can result in more
micelles for solubility, partitioning and subsequent absorption of nifedipine.
Therefore, in the presence of Miglyol810, higher plasma concentration of nifedipine

(

was obtained.

The dissolution profiles of the same formulations demonstrated a different picture in
simulated gastric fluid as shown in Figure 2. The Formulation B containing
CapmulMCM and D containing CremophorEL provided the highest dissolution rate
and extent while Formulation C containing Miglyol810 provided 50% release for
nifedipine after 60 minutes. The lowest dissolution profile was obtained with
Formulation A containing Capmul PG-8 which also provided the lowest
bioavailability of nifedipine. The only significant difference observed between in vitro
dissolution and in vivo plasma concentration profiles was with Formulations B and C.
Formulation B containing CapmulMCM provided the higher dissolution profile than
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Formulation C with Miglyol810. The opposite result observed the in vivo test was the
result of lipolysis that was absent during the dissolution tests.

As the result of the findings, it can be said that the dissolution test by itself is not
sufficient to predict the in vivo performance of formulations containing digestible
lipids.

The differences of the effects of CapmulMCM and CapmulPG-8 can be explained by
the contribution of the hydrophilic pait to the lipid solubility and dissolution of
nifedipine (Manuscript II and III). CapmulMCM is a glyce1ide ester of caprylic/capric
acid and has a molecular weight of 275. CapmulPG-8 is a propylene glycol ester of
caprylic acid and has a molecular weight of 202. Both lipids are surface active. The
dissolution of samples containing either lipid is carried out in an environment contains
3% Cremophor EL. Under these conditions, CapmulMCM formed particles of
approximately 12 nm and Capmul PG-8 around 700 nm, Table V. This may be one for
the reasons of the differences observed in dissolution, Figure 2. Similarly, the
formulation that was dispersed to larger particle size emulsion performed poorer
bioavailability, Figure 1. The particle size effect may be true for the formulations that
contain only mono-glycerides. However, it is not relevant for comparison of
Formulations C and B. If the particle size is a factor, the lower bioavailability should
be obtained for Formulation C containing Miglyol 810.
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The effect of solubility of nifedipine in lipids on bioavailability also showed an
inverse effect for the formulations without surfactant. The highest nifedipine solubility
was obtained in CapmulPG-8 and this formulation provided the lowest bioavailability.
Miglyol810 provided the lowest solubility for nifedipine, but the highest
bioavailability among the lipids excluding the formulation with surfactant, Table V.
This property affects the partitioning of nifedipine from the formulations to the
dissolution medium. Partitioning values were also included in the same table. It
provided the similar effect on bioavailability of nifedipine as dissolution does.

4. CONCLUSION
Bioavailability of nifedipine obtained with different lipid formulations in beagle dogs
showed that the type lipid and surfactant used in the formulation plays an important
role. Dissolution is a good predictor for the in vivo performance of nifedipine lipid
formulation when it was formulated with non-digestible lipids (mostly monoglycerides).

Although, the solubility of nifedipine in lipids, particle size of the formulation in
dissolution medium and partitioning of the drug from the formulation to dissolution
medium seem to affect the in vivo performance of the drug, dissolution rate and extent
of the formulation and digestibility of the lipid used in the formulations played the
major roles in bioavailability of nifedipine from lipid-based formulations.
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Table I. Lipid formulations that were used in the in vivo studies

Formulation

A

B

c

D

Nifedipine

100 mg

100 mg

100 mg

100 mg

CapmulPG-8

45 g

45 g

40.5 g

Capmul MCM
Miglyol810

45 g

4.5 g

Cremophor EL
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Table II. In vivo study experimental design (crossover study in fasted beagle
dogs)
Formulation

A

Dose (mg/dog)

Number of

Animal Numbers

10

capsules
4

Male
3

Female
3

4

3

3

4

3

3

4

3

3

One week wash-out period
B

10

One week wash-out period

c

10

One week wash-out period
D

10
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Table III. Nifedipine plasma concentrations (ng/mL)
Formulation A

Time (hr)

Ml

M2

M3

F4

F5

F6

Mean

SD

SEM

0

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.5

7.11

7.10

6.23

0.00

11.73

21.31

10.70

6.32

2.58

1

12.99

6.90

13.05 0.00

17.92

84.47

27.07

32.33

13.20

2

7.18

5.64

9.12

0.00

10.23

58.50

18.13

22.63

9.24

3

0.00

0.00

5.09

0.00

6.80

23.97

11.95

10.44

4.26

6

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

10

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

24

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Formulation B

0

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.5

19.46

27.45

38.20 14.93

9.44

34.55

24.01

11.31

4.62

1

9.91

28.12

31.41 22.50 48.19

67.23

34.56

20.28

8.28

2

19.23

18.12 32.27 19.22 21.24

19.93

21.67

5.29

2.16

3

8.71

10.14

27.10 16.35 19.07

18.76

16.69

6.71

2.74

6

8.27

0.00

13.56 0.00

13.05

0.00

11.63

2.92

1.19

10

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

24

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00
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Table Ill: Nifedipine plasma concentrations (ng/mL) (continued)

'

Formulation C

0.00

0.00

0.00

0.00

0.00

15.34 61.28

47.73 89.32 12.27

72.27

49.70

30.98

12.64

1

6.56

61.50

77.97 66.12

8.75

56.42

46.22

30.72

12.54

2

5.56

47.75

57.04 82.63 13.13

52.55

43.11

28.90

11.80

3

0.00

34.25

25.88 51.03 18.65

55.63

37.09

15.91

6.49

6

0.00

20.02

6.40 19.84

7.46

21.63

15.07

7.47

3.05

10

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

24

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

141.78 47.37 110.87 136.30 115.80 80.60

105 .45

35.77

14.60

1

57.84 38.94 48.63 46.61 69.23

54.09

52.56

10.43

4.26

2

18.58 47.49

24.85 44.95 89.69

37.35

43.82

25.13

10.26

3

16.91

13.87

33.98 32.81 76.15

16.90

31.77

23.40

9.55

6

5.52

6.41

32.02 19.31 53 .54

10.75

21.26

18.66

7.62

10

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

24

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0
0.5

0.00

0.00

0.00

0.00

Formulation D

0
0.5

0.00
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Table IV. Mean pharmacokinetic parameters of nifedipine lipid formulations with 6 beagle dogs
Formulation

Tmax ± sem 1

Cmax ± sem 2

AUCo-24 ± sem

(hr)

(ng/mL)

(ng.h/mL)

0.9 ± 0.1

23.66 ± 11.03

54.47 ± 18.80

Yes

0.83 ± 0.11

37.28 ± 7.39

154.64 ± 22.81

Skips

0.75 ± 0.11

55.84 ± 12.83

252.31 ± 54.24

Skips

0.58 ± 0.08

105.47 ± 14.59

362.44 ± 108.05

Inhibited

3

Digestibility

A (CapmulPG-8, propylene glycol
mono-capry late)
B (Capmul MCM, glyceryl monocaprylate/caprate)
-...J

C (Miglyol8 l 0, glyceryl tri-caprylate)

Vl

D (Miglyol8 l O/Cremophor EL, 9/ I)

1

2
3

p < 0.1806 Tmax values are not significantly different
p < 0.006 Cmax values are significantly different

p < 0.0235 AU Cs are significantly different

-

---------

Table V. Summary of in vitro results for nifedipine lipid formulations

Solubility

Dissolution

Partition

Particle size

(mg/g)

(%)at 60 min

coefficient (o/w)

(nm)

Miglyol 810

3.36 ± 0.03

50.19± 1.44

5.6 ± 0.45

Coarse

Capmul MCM

10.27 ± 0.09

96.05 ± 0.28

2 ± 0.18

11.6 ± 0.5

Capmul PG-8

16.98 ± 0.55

30.27 ± 3.54

9.6 ± 0.76

777 ± 32

Miglyol 810/

4.86 ± 0.04

97.23 ± 2.52

1.1 ± 0.02

10 ± 1.0

Formulation

- -..)

0\

Cremophor EL

Figure l: Nifedipine plasma profiles with four formulations
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Figure 2: Dissolution ofnifedipine from the formulations used for in vivo study
100
90
80
70
"O
~

60

0
"'
"'

50

~

40

>

:.a

30
20
10
0
0

10

20

30
tirre (min)

40

~

C.:apmuIPG-8 (Propylene mono-caprylate)

-

Capmul MCM (Glyceryl mono-caprylate/caprate)

--*- Miglyol810 (Glyceryl tri-caprylate)

""*"" Miglyol 81 O/Cremophor EL(9: 1)

178

50

60

(

SECTION III

APPENDIX

(

179

Figure 1. Calibration curve for griseofulvin in acetone

1.6
1.4
1.2
1
<!.)
u 0.8
c
c<l
.D 0.6
....
0
0.4
.D
0.2
c<l
0

y

(/.)

0.02

0.04

= 12.98lx + 0.0189
2
R =0.9955

0.06
0.08
concentration (mg/rnL)

(

180

0.1

0.12

(
Figure 2. Standart curve for HPLC analysis of nifedipine
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Figure 3. FT-IR spectrum of nifedipine in mineral
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Figure 4. FT-IR spectrum of griseofulvin in mineral
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Figure 5. FT-IR spectrum of oleic acid

o.u -

555.0 -

4.5 -

403.5 -

302.5-

2.0 -

(
3500

3000

2500
Wo;enumbers (cm-1)

184

2000

1500

1000

(
Figure 6. FT-IR spectrum of Captex GTO

12
1.1
1.0
0.9

0.8

'

0.7

i

0.6

i

0.5

)1~
\ 1\)

I' i

0.4

!

0.3

J

I

0.2

;
0 .1

-~.-----;-----)--;----r-~~-____ _,._,!,
3500

\____

-

-

v

.,./

- .- ,----~--- - , - - -

3000

1500

Wavenumbers (cm- 1)

185

~~
~
1000

(
Figure 2. Stan dart curve for HPLC analysis of nifedipine
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Figure 12. FT-IR spectrum of Capmul PG-8
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Figure 15. FT-IR spectrum of Captex200
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